


Review

Peroxides with Anthelmintic, Antiprotozoal, Fungicidal and Antiviral Bioactivity: Properties, Synthesis and Reactions

Vera A. Vil' ^{1,2,3}, Ivan A. Yaremenko ^{1,2,3}, Alexey I. Ilovaisky ¹ and Alexander O. Terent'ev ^{1,2,3,*} 

¹ N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Prospekt, 119991 Moscow, Russia; vil@ioc.ac.ru (V.A.V.); yaremenko@ioc.ac.ru (I.A.Y.); ilov@ioc.ac.ru (A.I.I.)

² Faculty of Chemical and Pharmaceutical Technology and Biomedical Products, D. I. Mendeleev University of Chemical Technology of Russia, 9 Miusskaya Square, 125047 Moscow, Russia

³ All-Russian Research Institute for Phytopathology, B. Vyazyomy, 143050 Moscow, Russia

* Correspondence: alterex@yandex.ru; Tel.: +7-916-385-4080

Received: 9 October 2017; Accepted: 30 October 2017; Published: 2 November 2017

Abstract: The biological activity of organic peroxides is usually associated with the antimalarial properties of artemisinin and its derivatives. However, the analysis of published data indicates that organic peroxides exhibit a variety of biological activity, which is still being given insufficient attention. In the present review, we deal with natural, semi-synthetic and synthetic peroxides exhibiting anthelmintic, antiprotozoal, fungicidal, antiviral and other activities that have not been described in detail earlier. The review is mainly concerned with the development of methods for the synthesis of biologically active natural peroxides, as well as its isolation from natural sources and the modification of natural peroxides. In addition, much attention is paid to the substantially cheaper biologically active synthetic peroxides. The present review summarizes 217 publications mainly from 2000 onwards.

Keywords: peroxides; anthelmintic; antiprotozoal; fungicidal; antiviral

1. Introduction

Peroxides are widely used in various areas of life [1–3]. Traditional and the most developed field is the application of peroxides as radical initiators in industrial processes in the manufacture of polymers from unsaturated monomers: styrenes, butadienes, chlorovinyls, ethylenes, acrylates, as well as in crosslinking of silicone rubbers, acrylonitrile-butadiene rubbers, fluororubbers, polyethylene, ethylene-propylene copolymer, etc. [4–9].

Hydrogen peroxide and peracids are active components of antiseptics and disinfectants [10–14]. Synthesis and mechanism of antiseptic action of hydrogen peroxide and the most common peracids (performic, peracetic, etc.) are elucidated in a few studies [15–17] and are not considered in this review.

Antimalarial properties of peroxides are currently intensively studied. Artemisinin (Qinghaosu) (1), a natural peroxide possessing high antimalarial activity, was isolated in 1971 from leaves of annual wormwood (*Artemisia annua*) in the context of the scientific program “Project 523”, initiated by Chinese government in 1967 [18–20]. The Nobel Prize in Physiology or Medicine 2015 was awarded to Chinese pharmaceutical chemist Tu Youyou “for her discoveries concerning a novel therapy against Malaria” [21–23]. Considering the development of antibiotic resistance of Plasmodium to some traditional drugs, such as quinine, chloroquine, and mefloquine, and other anti-parasitic ones, pharmaceuticals based on artemisinin and its semi-synthetic derivatives—dihydroartemisinin (2), artemether (3) and artesunate (4) (Figure 1)—are currently the most effective drugs against malaria [24–30].




Figure 1. Artemisinin and its semi-synthetic derivatives.

The modern trend in medicinal chemistry of peroxides is the search of effective anticancer drugs. The natural and synthetic peroxides exhibiting a cytotoxic effect on cancer cells already include hundreds of compounds [31–34]. Peroxides possessing antimalarial and cytotoxic activity are the subject of numerous studies [35–42], and are not considered in this review.

In the present review, we deal with natural, semi-synthetic and synthetic peroxides exhibiting anthelmintic, antiprotozoal, fungicidal, antiviral and other activities that have not been described in detail earlier. The review is mainly concerned with the synthesis of such peroxides, as well as its isolation from natural sources and covers literature published between 1912 and 2017.

There are several review articles, where the various kinds of the biological activity of artemisinin [43–45] and artemether [46,47]; the problems of trematode infection therapy with artemisinin, its derivatives and several synthetic ozonides [48]; and antiviral activity of artemisinin and artesunate [49] are discussed. Advances in the development of anti-parasitic peroxides are described in the review of Muraleedharan [50]. A number of reviews are devoted to promising anthelmintic peroxides [51]. Some natural antiviral peroxides are mentioned in the review [52]. However, none of these articles pay sufficient attention to the methods of peroxide synthesis.

Since peroxides with a related structure have different types of activity, the systematization of this review is based on the structure of the peroxide fragment (Figure 2). The first sections consider the preparation of cyclic peroxides in order of increasing cycle and the number of oxygen atoms in it, while the last section deals with peroxides of acyclic structure. The following abbreviations are used in describing the biological activity of peroxides: minimum inhibitory concentration (MIC), minimum lethal concentration (MLC), half maximal inhibitory concentration (IC_{50}), concentration of inhibiting 90% of activity (IC_{90}), half maximal effective concentration (EC_{50}), and median effective dose (ED_{50}) [53,54].





Figure 2. Reviewed cyclic and acyclic peroxides.

2. 1,2-Dioxolanes

A number of cyclic peroxides, many of which exhibit antibacterial, antifungal and anti-cancer activity, were isolated from the marine organisms, in particular from the sponges *Plakinidae* [55]. Plakinic acid A (5) effectively inhibits the growth of fungi *Saccharomyces cerevisiae* and *Penicillium atrounenetum* [56];


plakinic acid F (7) and *epi*-plakinic acid F (8) exhibit moderate antifungal activity against *Candida albicans* and *Aspergillus fumigatus* [57]; 1,2-dioxolane acids 9 and 10 inhibit the growth of *Candida albicans* [58]; and plakortide E (11) show good activity against *Trypanosoma brucei* (Scheme 1) [59].




Scheme 1. Antifungal and anti-parasitic activity of 1,2-dioxolanes, isolated from the sponges *Plakinidae*.

The first synthesis of diastereomeric saturated analogs of plakinic acids A, C and D 17 was reported in 1996 by Bloodworth and colleagues [60]. Peroxides 17 were prepared in four steps from ketones 12. In the first step, ketone 12 was condensed with ethyl 3-methylbut-2-enoate with formation cyclic lactones 13 hydrolysis, which led to acids 14. Peroxymercuration of esters 15 followed by reduction with sodium borohydride afforded 1,2-dioxolanes 16 saponification, which resulted in 1,2-dioxolanes 17 with carboxylic group (Scheme 2).

The synthesis of diastereomeric 1,2-dioxolanes 22 from alkynes was described [61]. Carboalumination of alkyne 18, followed by treatment of the intermediate alkenylaluminum with acetaldehyde, resulted in an allylic alcohol that was oxidized to enone 19. Conjugate addition of H₂O₂ to 19 in the presence of LiOH followed by acid-catalyzed esterification of diastereomeric dioxinole by 2-methoxyethanol provided alkoxydioxolane 20. Substitution of the methoxyethoxy group in 20 by the action of silyl keteneacetal ethyl thioacetal in the presence of TiCl₄ led to thioether 21 as a 1:1 mixture of two diastereomers. The hardly-separable *cis*- and *trans*-diastereomeric peroxides 22 were obtained as a result of hydrolysis with high yield (Scheme 3).



Scheme 2. The first synthesis of saturated analogs of plakinic acids 17.




Scheme 3. The synthesis of diastereomeric analogs of plakinic acids 22.


In 2006, the first asymmetric synthesis of plakinic acids was reported [62]. The key step of side chain construction was synthesis of diastereomeric allylic alcohols **25** from bromobenzene. This transformation included subsequent addition Mg-organic compound to crotonaldehyde with formation of alcohol **23**, Claisen homologation resulted in ester **24**, and reaction of an intermediate aldehyde with propenyl lithium (Scheme 4).

As a result of following transformation epoxy alcohol **29a** was prepared, which was oxidized into aldehyde; subsequent addition of methylmagnesium bromide resulted in isomeric secondary epoxy alcohols **30a** and **30b** (Scheme 5). After transformation of minor **30b** into **30a**, the latter was reduced to diol **31**. The treatment of diol **31** with stoichiometric quantity of TsCl and excess of *t*-BuOK led to oxetane **32**. The ring opening with TMSOTf provided easily separable 3-hydroxy hydroperoxides **33** and *epi*-**33**; **33** was converted into peroxy ketone **34** by subsequent silylation and oxidation. The ketone **34** was transformed into alkoxydioxolane **35**, and after that into thioester **36**. The desirable plakinic acids **38** were prepared by hydrolysis of methyl esters **37**. A similar strategy was used for the synthesis of stereomeric acids **39** from 3-hydroxy hydroperoxide *epi*-**33**.


A total synthesis of plakortide E (**11**) based on radical oxygenation of vinylcyclopropanes was reported [63,64]. The key intermediate 2-ethyl-1,1,2-cyclopropanetricarboxylate (**42**) prepared from methylene malonate (**40**) and α -chloro ester **41** was transformed into lactone **43**. The treatment of the latter with oxygen, Ph_2Se_2 and AIBN furnished spiro 1,2-dioxolane **44**, followed by lactone ring opening of **44** to form diol **45**. The precursor of the plakortide E **49** was synthesized from the iodo-derivative of 1,2-dioxolane **47** and the halogen derivative **48** by Negishi reaction. Desilylation of alcohol **49**, subsequent oxidation and Horner-Wadsworth-Emmons olefination provided ester **51** which was hydrolyzed with formation of plakortide E (**11**) (Scheme 6) [63].



Scheme 4. Construction of asymmetric plakinic acids side chain.




Scheme 5. Asymmetric synthesis of plakinic acids 38 and 39.




Scheme 6. Synthesis of plakortide E (11) by radical oxygenation of cyclopropanes.

A similar strategy based on the radical oxygenation of vinyl cyclopropanes was used for the synthesis of epiplakinic acid F (8) [65]. The vinyl cyclopropane 53 obtained from *trans*-1,2-cyclopropanedicarboxylate 52, was then converted to 1,2-dioxolane 55 (Scheme 7). After separation of the diastereomeric mixture isomer 55b was used for further transformations.

Enantiomerically pure 55b was reduced by LiBH₄ to alcohol 56, which was transformed to vinyl ether 57 by subsequent PCC oxidation and Wittig olefination. Oxidation of 57 to methyl ester 58, reductive ozonolysis of 58, and Wittig olefination gave predominantly the *Z*-isomer of vinyl iodide 59. The Negishi coupling of 59 with the halogen derivative led to the desired product 60. Desilylation of 60 followed by reduction of 61 resulted in saturated alcohol 62. The oxidation of 62 led to an aldehyde, the Wittig olefination of which provided the precursor 63 as a mixture of isomers. The product of photoinduced isomerization of this mixture was the *trans*-isomer 64. The target epiplakinic acid F (8) was obtained by alkaline hydrolysis of ester 64 (Scheme 8).




Scheme 7. Construction of 1,2-dioxolane fragment for epiplakinic acid F (8).




Scheme 8. Asymmetric synthesis of epiplakinic acid F (8).

The method of the preparation of andavadoic acid (**76**), a natural compound isolated from the sponges of *Plaxortis aff simplex*, based on the Isayama-Mukaiyama reaction and subsequent cyclization was known [66]. The starting substrate was epichlorohydrin (**65**), which was converted to epoxide **66** by a subsequent the organomagnesium compound addition and cyclization with the help of alkaline. The regioselective opening of the epoxide cycle of **66** by the lithium salt of ethyl propiolate in the presence of BF_3 resulted in the secondary alcohol **67** in almost quantitative yield. Alcohol **67** was converted into lactone **68** by reaction with Me_2CuLi , followed by acidification. Oxidation of lactone **68** to **69**, subsequent ring opening, oxidation of hydroxyl to the carbonyl group, and methylation resulted in epoxy ketone **70**, which was then converted to epoxy alkene **71**. Isayama-Mukaiyama peroxidation, the base-catalyzed cyclization of peroxide **72**, leading to a mixture of diastereomeric 1,2-dioxolanes **73/73a** followed by separation and thioacylation resulted in a peroxy thioester **74** which was converted into andavadoic acid (**76**) by subsequent reduction and hydrolysis of ester **75** (Scheme 9).




Scheme 9. Synthesis of andavadoic acid (**76**).

The symbiont of beetle of the southern pine (*Dendroctonus frontalis*), actinomycetous bacterium produces mycangimycin peroxide (**77**) with pronounced fungicidal activity (Scheme 10) [67]. Mycangimycin effectively inhibits growth of *Candida albicans* wild type, *C. albicans* ATCC10231, amphotericin-resistant strain *C. albicans* ATCC 200955, *Saccharomyces cerevisiae* and *Ophiostoma minus* [68].




Scheme 10. Natural peroxide mycangimycin and its fungicidal activity.

Two saturated analogs of mycangimycin were synthesized from alkene **78** and ester **79** (Scheme 11) [69]. The Kulinkovich reaction of **78** with **79** resulted in cyclopropane **80**, which formed 1,2-dioxolane **81** by a cobalt-catalyzed cleavage in the presence of oxygen. TfOH-catalyzed reduction of the alcohol **81** by silane led to 3,5-disubstituted 1,2-dioxolane **82**. The result of desilylation and oxidation of the obtained alcohol **83** is the first saturated analog of mycangimycin, acid **84**, which can be converted into ester **85**.





Scheme 11. The synthesis of saturated analogs of mycangimycin **84** and **85**.

The diterpenoid peroxide **86**, which has a weak fungicidal activity against *C. albicans*, was isolated from the liverwort *Jungermannia atrobrunnea* (Scheme 12) [70]. Dinardokanshone B (**87**), sesquiterpene peroxide, isolated from the roots and rhizomes of *Nardostachys chinensis* Batal. (Valerianaceae) showed significant enhancement effects on SERT activity (Scheme 12) [71].



Scheme 12. Terpene peroxides **86** and **87**.


Synthetic 1,2-dioxolanes **88** showed high in vitro activity against helminths *Schistosoma mansoni* (Scheme 13) [72].



NTS *S. mansoni* IC₅₀ < 20 μM


Scheme 13. 1,2-Dioxolanes **88** exhibiting high activity against schistosomiasis.

5,5-Dimethyl 1,2-dioxolanes **88a** were prepared by peroxidation of mesityl oxide (**89**) in the basic medium, followed by alkylation of the free hydroxyl group of 3-hydroxy-1,2-dioxolanes **90** (Scheme 14) [73]. Synthesis of cyclohexyl derivatives **88b** started from oxidation of alcohol **92** to an unsaturated ketone **93**, followed by Isayama-Mukaiyama peroxidation with formation of 1,2-dioxolane **94**. Further protection of hydroxyl group resulted in derivatives **88b** (Scheme 14) [73].



Scheme 14. Synthesis of anthelmintic 1,2-dioxolanes **88**.


The series of tricyclic monoperoxides **97** with 1,2-dioxolane moiety showed a high anti-schistosomal activity. The maximum activity was observed for compound **97a**, which revealed high worm burden reductions by 82.8% in *S. mansoni* mouse model (Scheme 15) [74]. Peroxides **97** can be obtained from β, δ-triketones **96** and hydrogen peroxide with use of either sulfuric acid [75], or boron trifluoride [76] as catalyst and co-solvent (Scheme 15).



Scheme 15. Synthesis of tricyclic monoperoxides **97** with high anti-schistosomal activity.

3. 1,2,4-Trioxolanes (Ozonides)

Various tetrasubstituted 1,2,4-trioxolanes (ozonides) have become the breakthrough in the field of biologically active synthetic peroxides. Nowadays ozonides are considered as the most promising candidates in the treatment of helminth diseases (Scheme 16). The 100% worm burden reductions were observed with a single oral dose of 1000 mg/kg OZ78 (**98**) in *Echinostoma caproni*-infected mice. A single dose of 100 mg/kg OZ78 (**98**) resulted in 100% worm burden reductions against juvenile and adult *Fasciola hepatica*-mouse model [77]. Single oral doses of 100 mg/kg OZ78 (**98**) is efficient against adult triclabendazole-resistant *F. hepatica*-infected rats [78]. Later, the efficacy of 1,2,4-trioxolane OZ78 (**98**) against an experimental infection with *Fasciola hepatica* in sheep was confirmed [79,80]. It was found that the spiroadamantane fragment and the carboxyl group in the OZ78 (**98**) are necessary for activity against *F. hepatica* [81].




Scheme 16. Tetrasubstituted synthetic ozonides with the highest anthelmintic activity.

The ozonides OZ78 (**98**) and OZ288 (**99**) showed low toxicity and high efficiency against helminth cultures *Schistosoma mansoni* and *S. japonicum* harboured in mice and hamsters with a single oral dose of 200 mg/kg [82,83]. Antichistosomal activity of OZ78 (**98**) against *S. japonicum* was confirmed in

experiments in mice and rabbits [84]. Later, the promising ozonide OZ418 (**100**) with high activity against both helminths of *S. mansoni* and *S. haematobium* was discovered [85].

Synthesis of tetrasubstituted unsymmetrical ozonides was discovered by Griesbaum and colleagues in 1995 (Scheme 17, top) [86,87]. Later this method was used for the diastereoselective synthesis of tetrasubstituted ozonides **103**. Peroxides **103** were prepared by ozonolysis of 2-adamantanone O-methyl oxime (**101**) in the presence of substituted cyclohexanones **102** (Scheme 17, bottom) [88,89]. 1,2,4-Trioxolane ring in compounds **103** is resistant to the action of a wide range of reagents, which allows to proceed a variety of modifications of the cyclohexane substituent [88].




Scheme 17. Synthesis of tetrasubstituted unsymmetrical ozonides.

4. 1,2-Dioxanes


A number of compounds containing 1,2-dioxane fragment isolated from the *Plakinidae* sponges showed high fungicidal and anti-trypanosomal activity. Plakinic acid B (**104**) exhibited good fungicidal activity against *Saccharomyces cerevisiae* and *Penicillium atrovenerum* (Scheme 18) [56]. The acid **105** in vitro inhibits the growth of fungi *Aspergillus fumigatus* with $IC_{90} = 5.6 \mu\text{g/mL}$ [58]. Compounds **106** and **107** were weakly active against *Staphylococcus aureus* [90]. 11,12-Didehydro-13-oxo-plakortide Q (**108**) was more active against *Trypanosoma brucei* [91]. Plakortide F acid (PFA) (**109**) showed high activity against *Candida albicans*, *Cryptococcus neoformans* and *A. fumigatus* [21]. Plakortides **110** and **111** also demonstrated high activity against a number of fungi [92]. Significant fungicidal activity of mixture of peroxyketal acids isolated from sea sponges was also reported [93].

A series of peroxyterpenes was isolated from the sponges *Diacarnus bismarckensis*, the most active of which, (+)-muqubilone B (**112**) and sigmosceptrellin B (**113**) showed high activity against *Trypanosoma brucei* [94]. (+)-Muqubilone B (**112**) and muqubilin (**114**) (isolated from the sponges *Prianos* [95]) were in vitro effective against herpes virus (HSV-1), muqubilin (**114**) and (–)-sigmosceptrellin B (**113**) exhibited in vitro activity against *Toxoplasma gondii* (Scheme 19) [96]. Muqubilin (**114**) possesses herbicidal activity against tobacco *Nicotiana tabacum* [97], as well as epimuqubilin (**115**) showed NO inhibitory activity [98]. Mycaperoxide B (**116**) displays high antiviral activity against vesicular stomatitis virus and herpes simplex virus type-1 (HCV-1) [99].


Several synthetic approaches to plakinic acids and their derivatives containing 1,2-dioxane ring were described. Natural 6-epiplakortolide E (**127**) was firstly synthesized from available 1-bromo-10-phenyldecane (**117**) in 10 steps by Diels-Alder reaction with singlet oxygen followed by iodolactonization (Scheme 20) [100]. In the first stage, the addition of the organomagnesium reagent to the unsaturated ketone resulted in enone **118**, which was converted to a tertiary alcohol **119**. Hydroboration of **119** led to diol **120**, protection of hydroxyl group of which provide silyl ether **121**. Diels-Alder reaction of diene **122** prepared by dehydration of **121** with singlet oxygen resulted in diastereomeric 1,2-dioxanes **123a** and **123b**. Deprotected diastereomer **124** was oxidized to acid **125**, subsequent iodolactonization of this acid gave bicycle **126**. Desirable 6-epiplakortolide E (**127**) was formed as result of radical reduction of iodine-containing bicycle **126**. It was noted that related plakortolide G (**128**) is active against the protozoa *Toxoplasma gondii* [101].



Scheme 18. 1,2-Dioxanes isolated from the sponges *Plakinidae*; their antifungal, antibacterial and anti-trypanosomal activity is also shown.





Scheme 19. Muquibilin (**114**) and related natural peroxides.




Scheme 20. Synthesis of 6-epiplakortolide E (127).

Asymmetric synthesis of alkoxy-1,2-dioxane **136** related to plakortolides was realized in 8 steps from carbonyl compounds **129** and **130** (Scheme 21) [102]. Enantioselective aldol reaction in first step resulted in aldol **131** which was converted into protected diol **132** in three steps. Diastereomeric 1,2-dioxanes **133a** and **133b** were formed by selective ozonolysis of double bond of **132**. Hydrozirconation of **133a** with following treatment by iodine led to the formation of vinyl iodide **134**, followed cross-coupling of one resulted in 1,2-dioxane **135**. Deprotection of **135** provided desirable peroxide **136**.

Natural endoperoxide 9,10-dihydroplakortin (**148**) and diastereomer **149** were synthesized through Evans' chiral auxiliary chemistry (Scheme 22) [103]. Alkylation of oxazolidinone **137** and subsequent reduction of **138** led to alcohol **139**, which was transformed into acrylic ester **140** (predominantly in *E*-configuration) by oxidation and Horner-Wadsworth-Emmons olefination. The ester **140** was reduced into corresponding alcohol, which was converted into iodide **141**, alkylation of oxazolidinone by which resulted in derivative **142**. The cleavage and olefination of **142** provided the ester **143**. The reduction of **143** furnished alcohol **144** followed by Sharpless epoxidation and protection of primary hydroxy-group with formation of epoxide **145**. Isayama-Mukaiyama peroxidation of epoxide **145** afforded mixture of diastereomeric 1,2-dioxanes **146** and **147** which were independently transformed into 9,10-dihydroplakortin (**148**) and 6-*epi*-dihydroplakortin (**149**).


Scheme 21. Asymmetric synthesis of 1,2-dioxane **136**.Scheme 22. Synthesis of natural endoperoxide 9,10-dihydroplakortin (**148**) and its diastereomer **149**.

In the synthesis of diastereomeric plakortolides **160** and **161**, the key steps are construction of protected diol **155** from protected 2-methyl glycidol **154** and vinyl bromide **152**, diastereoselective Mukaiyama addition of aldehyde **156** with formation of ester **157** and hydroperoxidation of alkene **158** with subsequent cyclization of **159** (Scheme 23) [104].



Scheme 23. Synthesis of diastereomeric plakortolides **160** and **161**.


Synthesis of analogs of plakinic acids, 1,2-dioxanes **166** with a pronounced anti-trypanosomal activity was proposed from *E*-hexen-4-ol (**162**) (Scheme 24) [105]. Swern oxidation of alcohol **162** and subsequent Wittig-olefination led to ester **163**. The reaction of unsaturated scaffold **163** with singlet oxygen and following cyclization provided 1,2-dioxane **164**, which was hydrolyzed to acid **165**. Derivatives **166** were prepared from ester **164** by consistent ozonolysis, reductive cleavage and Wittig reaction. Compounds **166** exhibited high activity against *T. brucei brucei* BF427.



Scheme 24. Synthesis of 1,2-dioxanes **166** with high anti-trypanosomal activity.

Diastereomeric cyclic peroxides **171**, one of which is the methyl ester of the mycaperoxide **B** (**116**), were prepared from protected hydroxyperoxide **167** (Scheme 25) [106]. In the first step,

peroxide **167** was oxidized to aldehyde **168**, which was converted into unsaturated ester **169** by Wittig reaction. Hydroperoxide **170** synthesized by deprotection of **169** was cyclized into 1,2-dioxane **171** and oxolane **172** by the action of triethylamine.




Scheme 25. Synthesis of diastereomeric peroxides **171**.

5. 1,2-Dioxenes

The plant *Chenopodium ambrosioides* is used for the production of essential chenopodium oil, which has been used as an anthelmintic agent for a long time [107,108]. The first isolation of the most active component—ascaridole (**174**), from the *Chenopodium ambrosioides* and the determination of its structure was dated to the beginning of the last century [109–112]. In the 1950s, the ascaridole (**174**) was completely characterized (Scheme 26) [113,114].


The first laboratory synthesis of ascaridole (**174**) was performed via photo-induced addition of singlet oxygen to terpene **173** by Schenck in 1944 (Scheme 26) [115]. Later, this reaction was realized in an industrial scale, because ascaridole was of great importance as an anthelmintic agent [116]. The method for the preparation of ascaridole using singlet oxygen generated in situ from sodium molybdate and hydrogen peroxide is known [117].



Scheme 26. Ascaridole synthesis (**174**).


It was shown that ascaridole (**174**) at concentration 4 mM almost completely inhibits the growth of fungi *Sclerotium rolfsii* [118]. Presently, the side effects of ascaridole on the gastrointestinal tract have been described, and ascaridole is currently not used [119].

In 1990, Gunasekera with colleagues isolated 1,2-dioxenes **175** and **176** from sea sponge *Plakortis angulospiculatus* (Scheme 27) [120]. It was shown that these natural peroxides exhibit antifungal activity against *Candida albicans* (MIC = 1.6 µg/mL).




Scheme 27. Antifungal natural 1,2-dioxenes **175**, **176**.

The total synthesis of stereoisomeric 1,2-dioxenes **185** was performed in 18 steps with a total yield of 2.8% (Scheme 28) [121]. The treatment of hydroxy ester **177** with *tert*-butyldiphenylsilyl chloride followed by DIBAL reduction and replacement of hydroxyl by iodine provided iodide **178**, which was converted into aldehyde **179** by subsequent asymmetric alkylation, reduction of prepared amide into alcohol and Swern oxidation. Alkene **180** was synthesized from sulfone derivative of aldehyde **179** to obtain mainly *trans*-isomer. Deprotection of **180**, nucleophilic substitution of hydroxyl by iodine, subsequent substitution of iodine by cyano-group and reduction of cyano-group led to aldehyde **181** which was then transformed into alkyne **182** by $\text{PPh}_3/\text{CBr}_4$ treatment and HBr elimination. The synthesis of enone **183** was performed by addition of ethylcuprate followed by propionyl chloride to alkyne **182**. The diene **184** was prepared predominantly in *trans*-conformation by condensation of enone **183** with lithium salt of propargyl phosphonate with subsequent hydroboration. Ene reaction of diene **184** with singlet oxygen and methylation by diazomethane resulted in 1,2-dioxenes **185a** and **185b**.




Scheme 28. Synthesis of stereoisomeric 1,2-dioxenes **185**.

The cyclic peroxide shuangkangsu (**186**) isolated from the buds of *Lonicera japonica* showed high antiviral activity against respiratory syncytial virus on the cell lines and influenza virus in the chicken embryos (Scheme 29) [122].




Scheme 29. Peroxide shuangkangsu (**186**) isolated from *Lonicera japonica*.

Ergosterol peroxide (**187**) isolated from different natural sources including the fungi *Pycnoporus cinnabarinus* demonstrated moderate antiviral activity against *Herpes simplex* and *Polio virus* [123], and also antifungal activity against pathogenic fungi *Microsporium canis*, *Trichophyton rubrum* and *Epidermophyton floccosum* (Scheme 30) [124]. Ergosterol peroxide acetate **189** was synthesized with quantitative yield by photo-oxidation of ergosterol acetate **188** in the presence of trityl tetrafluoroborate (Scheme 30) [125].




Scheme 30. Ergosterol peroxide (**187**), exhibited antiviral and antifungal activities and synthesis of its derivatives.

Analogues of ergosterol peroxide without multiple bonds in the side chain **194** were obtained by eosin Y catalyzed photooxidation of steroids **191** followed by hydrolysis and oxidation. Peroxides **194** showed significant ability to inhibit the growth of hepatitis B virus (Scheme 31) [126].



Scheme 31. Synthesis of **194**, antiviral analogs of ergosterol peroxide.

A number of 1,2-dioxenes **196** with simpler structure were synthesized from 1,3-butadienes **195**. Epoxidation of **196** resulted in 1,2-dioxanes **197** and **198**. These peroxides exhibit moderate antifungal activity against *Candida* family (Scheme 32) [127]. Later, a wide range of derivatives **196**, **197** and **198** that inhibits *Candida albicans* was synthesized [128]. 1,2-Dioxene **196a** showed high antifungal activity against *C. tropicalis* and *C. krusei* [129].




Scheme 32. Synthesis of 1,2-dioxenes **196** and their further modification.

6. 1,2,4-Trioxanes


Among the class of 1,2,4-trioxane, various aspects of the biological activity of artemisinin and its derivatives are studied most extensively. Synthetic strategies for peroxide ring construction in artemisinin were discussed in detail [130]. Compared with other methods the synthesis of artemisinin (**1**) based on dihydroartemisinic acid seems most preferable [131], as it can satisfy the demand for cheaper production of sufficient quantities of artemisinin. The key stages of the transformation of dihydroartemisinic acid into artemisinin (**1**) are described in the fundamental studies of Richard K. Haynes [132].

In addition to antimalarial and cytotoxic activity, artemisinin (1) has activity against trypanosomatides *Leishmania major* [133], *Leishmania donovani* [134], *Trypanosoma brucei rhodesiense* and *Trypanosoma cruzi* [135], as well as parasite *Toxoplasma gondii* (Scheme 33) [136]. Artemisinin showed a synergistic or additive effect in combination with itraconazole against fungi *Aspergillus fumigatus* [137], as well as moderate activity against *Fusarium oxysporum* [138]. Antiviral activity of artemisinin (1) was reported in few studies; inhibition of the human immunodeficiency virus (HIV-1) at 60% in peripheral blood mononuclear cells [139], the hepatitis C virus (HCV) in human liver cells [140], the bovine viral diarrhea virus (BVDV) [141], as well as hepatitis B virus [142] was shown.



Scheme 33. Artemisinin and various types of its bioactivity.


Artemisinin derivative, artemether (3), is actively used to treat schistosomiasis, a parasitic disease caused by flat worms of the genus *Schistosomiasis* [46,47]. A double-blind field trial in the Poyang Lake region (southern China) confirmed that artemether (3) significantly reduces the frequency and intensity of *S. japonicum* infection and does not cause side effects [143]. Despite the proven pathogenic effects on the reproductive system of *Fasciola hepatica* [144,145], artemether (3) had practically no effect in the treatment of fascioliasis in humans [146]. Artemether activity against *Leishmania major* [133], and *Toxoplasma gondii* [136,147] was detected; it was shown also that artemether is effective in the treatment of experimental rheumatoid arthritis [148,149]. Artemether (3) is obtained by reduction of artemisinin (1) to dihydroartemisinin (2) followed by methylation (Scheme 34) [150,151]. This synthesis can be performed in flow reactor [152,153].



Scheme 34. Synthesis of artemether (3) and its bioactivity.


Artesunate (4), artemisinin derivative containing free carboxylic group showed high efficiency against *S. japonicum* [154,155], and also in the therapy of fascioliasis caused by *Fasciola hepatica* or *Fasciola gigantica* (Scheme 35) [156]. It was determined that artesunate (4) causes changes in the reproductive system of *Fasciola hepatica* [144]. Antiviral activity of artesunate is displayed

against the hepatitis B virus [157] and the hepatitis C virus [158], the herpes virus (HHV) type 4 and type 6 [159,160], human cytomegalovirus (HCMV) [161–163], including therapy-resistant mutants of human cytomegalovirus [164]. Artesunate (4) is prepared by reaction of dihydroartemisinin (2) with succinic anhydride in basic conditions (Scheme 35) [152].



Scheme 35. Synthesis of artesunate (4) and its bioactivity.


The library of 10-deoxy-derivatives of artemisinin **205** showed high activity against parasites *Leishmania donovani* (Scheme 36). Synthesis of **205** was performed from artemisitene **199** by radical addition of compound **200** followed by reduction of carbonyl group in **202**. Dehydration and deprotection resulted in phenol **204**, which formed a series of compounds **205** by reaction with derivatives of carboxylic and sulfonic acids [165].



Scheme 36. Antileishmaniasis derivatives of artemisinin **205**.


Attempts to synthesize the antitoxoplasma derivatives of artemisinin have been made [147,166], however their in vitro activity did not exceed the activity of artemether (3).

Among artemisinin derivatives tested for fungicidal activity, anhydrodihydroartemisinin (206) and arteether (207) were most active against *Cryptococcus neoformans* [167], their activity surpassed the one of amphotericin B. Both derivatives were obtained [168,169] in one step from dihydroartemisinin (2) (Scheme 37). Later it was found that arteether (207) [170] exhibits moderate antiviral activity against human immunodeficiency virus and anhydrodihydroartemisinin (206) [171] is high active against hepatitis B virus.



Scheme 37. Antifungal and antiviral artemisinin derivatives— anhydrodihydroartemisinin (206) and arteether (207).


High antiviral activity against human immunodeficiency virus [170] was demonstrated by butyl-derivative of artemisinin 209, prepared via photo-oxidation of alcohol 208 with 12% yield (Scheme 38) [172].




Scheme 38. Antiviral artemisinin derivative 209.

Combination of dihydroartemisinin (2) with antiviral drug azidothymidine (210) resulted in compound 211 exhibited both antimalarial as antiviral activity (Scheme 39) [173].

A new trend in the medical chemistry of artemisinin derivatives is the synthesis of dimers and trimers. Among a series of artemisinin dimers obtained by condensation of dihydroartemisinin (2) with binucleophile, compounds 212 and 213 showed the highest activity against fungi *Cryptococcus neoformans* and parasites *Leishmania donovani*, respectively (Scheme 40) [174].



Scheme 39. Synthesis of hybrid **211** based on dihydroartemisinin **2** and azidothymidine **210**.








Scheme 40. Synthesis of artemisinin dimers **212** and **213** with antifungal and anti-parasitic activity.

Dimers and trimers of artemisinin showed antiviral activity were summarized in Table 1.


Table 1. Dimers and trimers of artemisinin showed antiviral activity.

No.	Dimer/Trimer Structure	Synthesis	Bioactivity
1	<p style="text-align: center;">214</p>	from artemisinin (1) 3 steps, 67% [175]	<i>HCMV</i> EC ₅₀ = 0.15 μM [176,177]
2	<p style="text-align: center;">215</p>	from 214 3 steps, 42% [178]	<i>HCMV</i> EC ₅₀ = 0.06 μM [176]

Table 1. Cont.


No.	Dimer/Trimer Structure	Synthesis	Bioactivity
3	 <p>216</p>	from 214 1 step, 96% [179]	HCMV EC ₅₀ = 0.04 μM [180–182]
4	 <p>217</p>	from 214 1 step, 25% [183]	HCMV EC ₅₀ = 44 nM [183]
5	 <p>218</p>	from <i>threo</i> - 214 and artesunate (4), 1 step, quantitative yield [184]	HCMV EC ₅₀ = 0.04 μM [184,185]
6	 <p>219</p>	from <i>threo</i> - 214 1 step, 67% [186]	HCMV EC ₅₀ = 0.11 μM [186]
7	 <p>220</p>	not reported	HCV EC ₅₀ = 3.2 μM [187]

Synthetic 1,2,4-trioxanes **223** obtained by condensation of hydroxy-hydroperoxide **221** with adamantane followed by hydrolysis of ester **222** showed high in vivo activity against helminths *Fasciola hepatica* in rats (Scheme 41) [188].


Scheme 41. Anthelmintic activity of synthetic 1,2,4-trioxanes **223**.

7. 1,2,4,5-Tetraoxanes


Synthetic 1,2,4,5-tetraoxane **226** [189], prepared by condensation of *bis*-hydroperoxide **224** with adamantanonone followed by hydrolysis ester **225**, showed high in vivo activity against helminths *Fasciola hepatica* in rats (Scheme 42) [188].

Scheme 42. Synthesis of 1,2,4,5-tetraoxane **226** with high anthelmintic activity.

Based on related 1,2,4,5-tetraoxanes **227**, hybrids **229** with a fragment of an anthelmintic drug praziquantel **228** were obtained (Scheme 43) [190]. Synthesized hybrids **229** exhibit high activity against *Schistosoma japonicum* and *Schistosoma mansoni* [191].

Scheme 43. Synthesis of hybrids **229** as anti-schistosomal agents.

Bridged 1,2,4,5-tetraoxanes **231** demonstrated high *in vitro* and *in vivo* activity against trematodes *Schistosoma mansoni* [74,192]. The best result was shown for adamantane-substituted tetraoxane **231a** which caused 75% worm burden reductions in *S. mansoni* harbored in mice following the administration of peroxide at single oral dose of 400 mg/kg. Peroxides **231** were synthesized from β -diketones **230** and H_2O_2 with good yields by the action of various acids: sulfuric [193], phosphomolybdic and phosphotungstic acids [194] (Scheme 44).




Scheme 44. Synthesis of bridged 1,2,4,5-tetraoxanes **231**.

8. Acyclic Peroxides


Many acyclic peroxides are applied as oxidants in organic synthesis [195,196]. Benzoyl peroxide (**234**) is actively used in the food industry as a flour bleach [197–199], and in pharmaceuticals. The first mention about the medical using of benzoyl peroxide dates back to 1929, where Lyon and Reynolds reported effective treatment of burns, wounds and varicose veins by benzoyl peroxide [200]. Subsequently it was found that it has antibacterial [201,202], anti-inflammatory [203], cheratolic [204], and wound-healing [205,206] effects. Presently, benzoyl peroxide is widely used agent for acne treatment because of its efficacy and good tolerability in patients [207,208]. Benzoyl peroxide is a good alternative to monotherapy with antibiotics for the treatment of *Acne vulgaris* caused antibiotic-resistant strains, for example *Propionibacterium acnes* [209,210].

Benzoyl peroxide is commercially produced by the reaction of benzoyl chloride (**232**), sodium hydroxide and hydrogen peroxide (Scheme 45, top) [211,212]. Benzoyl peroxide can also be prepared from benzoic anhydride (**233**) by the action of an alkali metal perborate in an aqueous solution (Scheme 45, bottom) [213].




Scheme 45. Benzoyl peroxide (**234**) production.

Oxanthromicin (**235**) isolated from bacteria *Actinomadura* sp. [214] showed high antifungal activity against *Trichophyton mentagrophytes*, *Micosporum canis*, *M. gypseum*, *Epidermophyton floccosum*, *Candida albicans*, and *Aspergillus niger* (Scheme 46) [215].



Scheme 46. Antifungal natural acyclic peroxide, oxanthromicin (**235**).


Hydroperoxide **236** obtained by biotransformation of *Artemisia cina* metabolites exhibits high in vitro activity against protozoa *Trypanosoma brucei* (Scheme 47) [216].



Trypanosoma brucei EC₅₀ ($\mu\text{g/mL}$) 0.40


Scheme 47. Anti-trypanosomal hydroperoxide **236**.

Four monoterpene hydroperoxides **237a–d** were isolated from aerial parts of *Chenopodium ambrosioides*. Minimum lethal concentration (MLC) in vitro of its peroxides against *Trypanosoma cruzi* was 1.2, 1.6, 3.1, and 0.8 μM , respectively (Scheme 48) [107].



Scheme 48. Hydroperoxides **237a–d** isolated from *Chenopodium ambrosioides*.

A geminal bis-hydroperoxides **239** synthesized from cyclic ketones **238** show pronounced in vitro antimicrobial and antifungal activity against *B. cereus*, *E. coli*, *P. aeruginosa*, *S. aureus*, *C. albicans*, and *A. niger* comparable with the effect of some antiseptics and, to a lesser extent, antibiotics (Scheme 49) [217].



Scheme 49. Antimicrobial and antifungal geminal *bis*-hydroperoxides **239**.

9. Conclusions

The biological activity of organic peroxides is usually associated with the antimalarial properties of artemisinin and its derivatives. However, the analysis of published data indicates that organic peroxides exhibit a variety of biological activity—anthelmintic, antifungal, antiviral, etc.—which is still being given insufficient attention.

Efforts of synthetic chemists are currently directed at the development of methods for the synthesis of biologically active natural peroxides, the modification of natural peroxides and the search of synthetic peroxides, which are not inferior to their natural and semisynthetic analogs, but are substantially cheaper. It seems that progress in the synthesis of biologically active peroxides will be mainly related to the last two directions.

In view of very dynamic development of these areas of medical chemistry, in the near future, one should expect a breakthrough in the synthesis of biologically active peroxides and in understanding of its action with respect to a wide range of bio-targets.

Acknowledgments: The authors are grateful to the Russian Science Foundation (Grant 17-73-10364) for the financial support.

Author Contributions: All authors have contributed substantially: V.A.V., I.A.Y., I.A.I. and A.O.T. wrote the manuscript; and V.A.V. and I.A.Y. researched the literature and wrote the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Patnaik, P. Peroxides, organic. In *A Comprehensive Guide to the Hazardous Properties of Chemical Substances*; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2006; pp. 719–740.
- Liebman, J.F.; Greer, A. *The Chemistry of Peroxides*; John Wiley & Sons: Hoboken, NJ, USA, 2006; Volume 3.
- Klapötke, T.M.; Wloka, T. Peroxide explosives. In *Patai's Chemistry of Functional Groups*; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2009.
- Denisov, E.T.; Denisova, T.G.; Pokidova, T.S. Diacyl peroxides, peroxy esters, polyatomic, and organometallic peroxides. In *Handbook of Free Radical Initiators*; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2005; pp. 129–282.
- Gaylord, N.G.; Mandal, B.M.; Martan, M. Peroxide-induced polymerization of norbornene. *J. Polym. Sci. Polym. Lett. Ed.* **1976**, *14*, 555–559. [[CrossRef](#)]
- Emami, S.H.; Salovey, R.; Hogen-Esch, T.E. Peroxide-mediated crosslinking of poly(ethylene oxide). *J. Polym. Sci. Part A Polym. Chem.* **2002**, *40*, 3021–3026. [[CrossRef](#)]
- Russell, K.E. Free radical graft polymerization and copolymerization at higher temperatures. *Prog. Polym. Sci.* **2002**, *27*, 1007–1038. [[CrossRef](#)]
- Adam, W. *Peroxide Chemistry: Mechanistic and Preparative Aspects of Oxygen Transfer*; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2005.
- Mishra, M.; Yagci, Y. *Handbook of Vinyl Polymers: Radical Polymerization, Process, and Technology*, 2nd ed.; CRC Press, Taylor & Francis Group: Boca Raton, FL, USA, 2008; p. 784.
- Ukuku, D.O.; Bari, L.; Kawamoto, S. Hydrogen peroxide. In *Decontamination of Fresh and Minimally Processed Produce*; Wiley-Blackwell: Hoboken, NJ, USA, 2012; pp. 197–214.
- Kitis, M. Disinfection of wastewater with peracetic acid: A review. *Environ. Int.* **2004**, *30*, 47–55. [[CrossRef](#)]

12. Chassot, A.L.C.; Poisl, M.I.P.; Samuel, S.M.W. In vivo and in vitro evaluation of the efficacy of a peracetic acid-based disinfectant for decontamination of acrylic resins. *Braz. Dent. J.* **2006**, *17*, 117–121. [[CrossRef](#)] [[PubMed](#)]
13. Baldry, M.G.C.; French, M.S. Disinfection of sewage effluent with peracetic acid. *Water Sci. Technol.* **1989**, *21*, 203–206.
14. Alvaro, J.E.; Moreno, S.; Dianez, F.; Santos, M.; Carrasco, G.; Urrestarazu, M. Effects of peracetic acid disinfectant on the postharvest of some fresh vegetables. *J. Food Eng.* **2009**, *95*, 11–15. [[CrossRef](#)]
15. McDonnell, G. The use of hydrogen peroxide for disinfection and sterilization applications. In *Patai's Chemistry of Functional Groups*; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2009.
16. Omidbakhsh, N. A new peroxide-based flexible endoscope-compatible high-level disinfectant. *Am. J. Infect. Control* **2006**, *34*, 571–577. [[CrossRef](#)] [[PubMed](#)]
17. Luukkonen, T.; Pehkonen, S.O. Peracids in water treatment: A critical review. *Crit. Rev. Environ. Sci. Technol.* **2017**, *47*, 1–39. [[CrossRef](#)]
18. Mao, W.; Zhang, Y.; Zhang, A. Discovery of antimalarial drug artemisinin and beyond. In *Case Studies in Modern Drug Discovery and Development*; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2012; pp. 227–256.
19. Tu, Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. *Nat. Med.* **2011**, *17*, 1217–1220. [[CrossRef](#)] [[PubMed](#)]
20. White, N.J.; Hien, T.T.; Nosten, F.H. A brief history of qinghaosu. *Trends Parasitol.* **2015**, *31*, 607–610. [[CrossRef](#)] [[PubMed](#)]
21. Xu, T.; Feng, Q.; Jacob, M.R.; Avula, B.; Mask, M.M.; Baerson, S.R.; Tripathi, S.K.; Mohammed, R.; Hamann, M.T.; Khan, I.A.; et al. The marine sponge-derived polyketide endoperoxide plakortide f acid mediates its antifungal activity by interfering with calcium homeostasis. *Antimicrob. Agents Chemother.* **2011**, *55*, 1611–1621. [[CrossRef](#)] [[PubMed](#)]
22. Tu, Y.Y.; Ni, M.Y.; Zhong, Y.R.; Li, L.N.; Cui, S.L.; Zhang, M.Q.; Wang, X.Z.; Liang, X.T. Studies on the constituents of artemisia annua l. (author's transl). *Yao Xue Xue Bao* **1981**, *16*, 366–370. [[PubMed](#)]
23. Miller, L.H.; Su, X. Artemisinin: Discovery from the Chinese herbal garden. *Cell* **2011**, *146*, 855–858. [[CrossRef](#)] [[PubMed](#)]
24. Robert, A.; Dechy-Cabaret, O.; Cazelles, J.; Meunier, B. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. *Acc. Chem. Res.* **2002**, *35*, 167–174. [[CrossRef](#)] [[PubMed](#)]
25. Gelb, M.H. Drug discovery for malaria: A very challenging and timely endeavor. *Curr. Opin. Chem. Biol.* **2007**, *11*, 440–445. [[CrossRef](#)] [[PubMed](#)]
26. Capela, R.; Oliveira, R.; Gonçalves, L.M.; Domingos, A.; Gut, J.; Rosenthal, P.J.; Lopes, F.; Moreira, R. Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: Design, synthesis and preliminary sar for antiplasmodial activity and falcipain-2 inhibition. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3229–3232. [[CrossRef](#)] [[PubMed](#)]
27. Jones, M.; Mercer, A.E.; Stocks, P.A.; La Pensée, L.J.I.; Cosstick, R.; Park, B.K.; Kennedy, M.E.; Piantanida, I.; Ward, S.A.; Davies, J.; et al. Antitumour and antimalarial activity of artemisinin-acridine hybrids. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 2033–2037. [[CrossRef](#)] [[PubMed](#)]
28. White, N.J. Qinghaosu (artemisinin): The price of success. *Science* **2008**, *320*, 330–334. [[CrossRef](#)] [[PubMed](#)]
29. Shah, F.; Zhang, S.-Q.; Kandhari, S.P.; Mukherjee, P.; Chittiboyina, A.; Avery, M.A.; Avery, B.A. In vitro erythrocytic uptake studies of artemisinin and selected derivatives using lc-ms and 2d-qsar analysis of uptake in parasitized erythrocytes. *Bioorg. Med. Chem.* **2009**, *17*, 5325–5331. [[CrossRef](#)] [[PubMed](#)]
30. Mäser, P.; Wittlin, S.; Rottmann, M.; Wenzler, T.; Kaiser, M.; Brun, R. Antiparasitic agents: New drugs on the horizon. *Curr. Opin. Pharmacol.* **2012**, *12*, 562–566. [[CrossRef](#)] [[PubMed](#)]
31. Dembitsky, V.M. Bioactive peroxides as potential therapeutic agents. *Eur. J. Med. Chem.* **2008**, *43*, 223–251. [[CrossRef](#)] [[PubMed](#)]
32. Ibrahim, S.R.M.; Ebel, R.; Wray, V.; Müller, W.E.G.; Edrada-Ebel, R.; Proksch, P. Diacarpoxides, norterpene cyclic peroxides from the sponge diacarnus megaspinothabdos. *J. Nat. Prod.* **2008**, *71*, 1358–1364. [[CrossRef](#)] [[PubMed](#)]
33. Liu, D.-Z.; Liu, J.-K. Peroxy natural products. *Nat. Prod. Bioprospect.* **2013**, *3*, 161–206. [[CrossRef](#)]
34. Li, H.; Huang, H.; Shao, C.; Huang, H.; Jiang, J.; Zhu, X.; Liu, Y.; Liu, L.; Lu, Y.; Li, M.; et al. Cytotoxic norsesquiterpene peroxides from the endophytic fungus talaromyces flavus isolated from the mangrove plant sonneratia apetala. *J. Nat. Prod.* **2011**, *74*, 1230–1235. [[CrossRef](#)] [[PubMed](#)]

35. Meshnick, S.R.; Jefford, C.W.; Posner, G.H.; Avery, M.A.; Peters, W. Second-generation antimalarial endoperoxides. *Parasitol. Today* **1996**, *12*, 79–82. [[CrossRef](#)]
36. Ploypradith, P. Development of artemisinin and its structurally simplified trioxane derivatives as antimalarial drugs. *Acta Trop.* **2004**, *89*, 329–342. [[CrossRef](#)] [[PubMed](#)]
37. Tang, Y.; Dong, Y.; Vennerstrom, J.L. Synthetic peroxides as antimalarials. *Med. Res. Rev.* **2004**, *24*, 425–448. [[CrossRef](#)] [[PubMed](#)]
38. Jefford, C.W. New developments in synthetic peroxidic drugs as artemisinin mimics. *Drug Discov. Today* **2007**, *12*, 487–495. [[CrossRef](#)] [[PubMed](#)]
39. Opsenica, D.M.; Šolaja, B.A. Antimalarial peroxides. *J. Serb. Chem. Soc.* **2009**, *74*, 1155–1193. [[CrossRef](#)]
40. Dembitsky, V.M.; Gloriovova, T.A.; Poroikov, V.V. Natural peroxy anticancer agents. *Mini Rev. Med. Chem.* **2007**, *7*, 571–589. [[CrossRef](#)] [[PubMed](#)]
41. Jung, M.; Kim, H.; Lee, K.; Park, M. Naturally occurring peroxides with biological activities. *Mini Rev. Med. Chem.* **2003**, *3*, 159–165. [[CrossRef](#)] [[PubMed](#)]
42. Chaturvedi, D.; Goswami, A.; Pratim Saikia, P.; Barua, N.C.; Rao, P.G. Artemisinin and its derivatives: A novel class of anti-malarial and anti-cancer agents. *Chem. Soc. Rev.* **2010**, *39*, 435–454. [[CrossRef](#)] [[PubMed](#)]
43. Lee, S. Artemisinin, promising lead natural product for various drug developments. *Mini Rev. Med. Chem.* **2007**, *7*, 411–422. [[CrossRef](#)] [[PubMed](#)]
44. Pandey, N.; Pandey-Rai, S. Updates on artemisinin: An insight to mode of actions and strategies for enhanced global production. *Protoplasma* **2016**, *253*, 15–30. [[CrossRef](#)] [[PubMed](#)]
45. Yao, W.; Wang, F.; Wang, H. Immunomodulation of artemisinin and its derivatives. *Sci. Bull.* **2016**, *61*, 1399–1406. [[CrossRef](#)]
46. Utzinger, J.; Shuhua, X.; N’Goran, E.K.; Bergquist, R.; Tanner, M. The potential of artemether for the control of schistosomiasis. *Int. J. Parasitol.* **2001**, *31*, 1549–1562. [[CrossRef](#)]
47. Utzinger, J.; Xiao, S.; Keiser, J.; Chen, M.; Zheng, J.; Tanner, M. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. *Curr. Med. Chem.* **2001**, *8*, 1841–1860. [[CrossRef](#)] [[PubMed](#)]
48. Keiser, J.; Utzinger, J. Food-borne trematodiasis: Current chemotherapy and advances with artemisinins and synthetic trioxolanes. *Trends Parasitol.* **2007**, *23*, 555–562. [[CrossRef](#)] [[PubMed](#)]
49. Efferth, T.; Romero, M.R.; Wolf, D.G.; Stamminger, T.; Marin, J.J.G.; Marschall, M. The antiviral activities of artemisinin and artesunate. *Clin. Infect. Dis.* **2008**, *47*, 804–811. [[CrossRef](#)] [[PubMed](#)]
50. Muraleedharan, K.M.; Avery, M.A. Progress in the development of peroxide-based anti-parasitic agents. *Drug Discov. Today* **2009**, *14*, 793–803. [[CrossRef](#)] [[PubMed](#)]
51. Panic, G.; Duthaler, U.; Speich, B.; Keiser, J. Repurposing drugs for the treatment and control of helminth infections. *Int. J. Parasitol. Drugs Drug Resist.* **2014**, *4*, 185–200. [[CrossRef](#)] [[PubMed](#)]
52. Qiu, L.-P.; Chen, K.-P. Anti-hbv agents derived from botanical origin. *Fitoterapia* **2013**, *84*, 140–157. [[CrossRef](#)] [[PubMed](#)]
53. Neubig, R.R.; Spedding, M.; Kenakin, T.; Christopoulos, A. International union of pharmacology committee on receptor nomenclature and drug classification. Xxxviii. Update on terms and symbols in quantitative pharmacology. *Pharmacol. Rev.* **2003**, *55*, 597–606. [[CrossRef](#)] [[PubMed](#)]
54. Sebaugh, J.L. Guidelines for accurate ec50/ic50 estimation. *Pharm. Stat.* **2011**, *10*, 128–134. [[CrossRef](#)] [[PubMed](#)]
55. Ann Casteel, D. Peroxy natural products. *Nat. Prod. Rep.* **1999**, *16*, 55–73. [[CrossRef](#)]
56. Phillipson, D.W.; Rinehart, K.L. Antifungal peroxide-containing acids from two caribbean sponges. *J. Am. Chem. Soc.* **1983**, *105*, 7735–7736. [[CrossRef](#)]
57. Chen, Y.; Killday, K.B.; McCarthy, P.J.; Schimoler, R.; Chilson, K.; Selitrennikoff, C.; Pomponi, S.A.; Wright, A.E. Three new peroxides from the sponge plakinastrella species. *J. Nat. Prod.* **2001**, *64*, 262–264. [[CrossRef](#)] [[PubMed](#)]
58. Chen, Y.; McCarthy, P.J.; Harmody, D.K.; Schimoler-O’Rourke, R.; Chilson, K.; Selitrennikoff, C.; Pomponi, S.A.; Wright, A.E. New bioactive peroxides from marine sponges of the family plakinidae. *J. Nat. Prod.* **2002**, *65*, 1509–1512. [[CrossRef](#)] [[PubMed](#)]
59. Oli, S.; Abdelmohsen, U.R.; Hentschel, U.; Schirmeister, T. Identification of plakortide e from the caribbean sponge plakortis halichondroides as a trypanocidal protease inhibitor using bioactivity-guided fractionation. *Mar. Drugs* **2014**, *12*, 2614–2622. [[CrossRef](#)] [[PubMed](#)]

60. Bloodworth, A.J.; Bothwell, B.D.; Collins, A.N.; Maidwell, N.L. A short synthesis of naturally occurring and other analogues of plakinic acids that contain the 1,2-dioxolane group. *Tetrahedron Lett.* **1996**, *37*, 1885–1888. [[CrossRef](#)]
61. Dussault, P.H.; Liu, X. Lewis acid-mediated displacements of alkoxydioxolanes: Synthesis of a 1,2-dioxolane natural product. *Org. Lett.* **1999**, *1*, 1391–1393. [[CrossRef](#)] [[PubMed](#)]
62. Dai, P.; Trullinger, T.K.; Liu, X.; Dussault, P.H. Asymmetric synthesis of 1,2-dioxolane-3-acetic acids: Synthesis and configurational assignment of plakinic acid A. *J. Org. Chem.* **2006**, *71*, 2283–2292. [[CrossRef](#)] [[PubMed](#)]
63. Sun, X.-Y.; Tian, X.-Y.; Li, Z.-W.; Peng, X.-S.; Wong, H.N.C. Total synthesis of plakortide e and biomimetic synthesis of plakortone B. *Chemistry* **2011**, *17*, 5874–5880. [[CrossRef](#)] [[PubMed](#)]
64. Zhao, Q.; Wong, H.N.C. Synthetic studies toward plakortide E: Application of the feldman oxygenation to synthesis of highly substituted 1,2-dioxolanes. *Tetrahedron* **2007**, *63*, 6296–6305. [[CrossRef](#)]
65. Tian, X.-Y.; Han, J.-W.; Zhao, Q.; Wong, H.N.C. Asymmetric synthesis of 3,3,5,5-tetrasubstituted 1,2-dioxolanes: Total synthesis of epiplakinic acid f. *Org. Biomol. Chem.* **2014**, *12*, 3686–3700. [[CrossRef](#)] [[PubMed](#)]
66. Barnych, B.; Fenet, B.; Vatéle, J.-M. Asymmetric synthesis of andavadoic acid via base-catalyzed 5-exo-tet cyclization of a β -hydroperoxy epoxide. *Tetrahedron* **2013**, *69*, 334–340. [[CrossRef](#)]
67. Scott, J.J.; Oh, D.-C.; Yuceer, M.C.; Klepzig, K.D.; Clardy, J.; Currie, C.R. Bacterial protection of beetle–fungus mutualism. *Science* **2008**, *322*, 63. [[CrossRef](#)] [[PubMed](#)]
68. Oh, D.-C.; Scott, J.J.; Currie, C.R.; Clardy, J. Mycangimycin, a polyene peroxide from a mutualist streptomyces sp. *Org. Lett.* **2009**, *11*, 633–636. [[CrossRef](#)] [[PubMed](#)]
69. Nguyen, T.L.; Ferrié, L.; Figadère, B. Synthesis of 3,5-disubstituted-1,2-dioxolanes: Access to analogues of mycangimycin and some rearrangement products. *Tetrahedron Lett.* **2016**, *57*, 5286–5289. [[CrossRef](#)]
70. Qu, J.-B.; Zhu, R.-L.; Zhang, Y.-L.; Guo, H.-F.; Wang, X.-N.; Xie, C.-F.; Yu, W.-T.; Ji, M.; Lou, H.-X. Ent-kaurane diterpenoids from the liverwort *Jungermannia atrobrunnea*. *J. Nat. Prod.* **2008**, *71*, 1418–1422. [[CrossRef](#)] [[PubMed](#)]
71. Wu, H.-H.; Chen, Y.-P.; Ying, S.-S.; Zhang, P.; Xu, Y.-T.; Gao, X.-M.; Zhu, Y. Dinardokanshones A and B, two unique sesquiterpene dimers from the roots and rhizomes of *nardostachys chinensis*. *Tetrahedron Lett.* **2015**, *56*, 5851–5854. [[CrossRef](#)]
72. Ingram, K.; Schiaffo, C.E.; Sittiwong, W.; Benner, E.; Dussault, P.H.; Keiser, J. In vitro and in vivo activity of 3-alkoxy-1,2-dioxolanes against *Schistosoma mansoni*. *J. Antimicrob. Chemother.* **2012**, *67*, 1979–1986. [[CrossRef](#)] [[PubMed](#)]
73. Schiaffo, C.E.; Rottman, M.; Wittlin, S.; Dussault, P.H. 3-Alkoxy-1,2-dioxolanes: Synthesis and evaluation as potential antimalarial agents. *ACS Med. Chem. Lett.* **2011**, *2*, 316–319. [[CrossRef](#)] [[PubMed](#)]
74. Ingram, K.; Yaremenko, I.A.; Krylov, I.B.; Hofer, L.; Terent'ev, A.O.; Keiser, J. Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, aliphatic peroxides, and tricyclic monoperoxides. *J. Med. Chem.* **2012**, *55*, 8700–8711. [[CrossRef](#)] [[PubMed](#)]
75. Terent'ev, A.O.; Yaremenko, I.A.; Chernyshev, V.V.; Dembitsky, V.M.; Nikishin, G.I. Selective synthesis of cyclic peroxides from triketones and H₂O₂. *J. Org. Chem.* **2012**, *77*, 1833–1842. [[CrossRef](#)] [[PubMed](#)]
76. Terent'ev, A.O.; Yaremenko, I.A.; Vil', V.A.; Dembitsky, V.M.; Nikishin, G.I. Boron trifluoride as an efficient catalyst for the selective synthesis of tricyclic monoperoxides from β,δ -triketones and H₂O₂. *Synthesis* **2013**, *45*, 246–250. [[CrossRef](#)]
77. Keiser, J.; Utzinger, J.; Tanner, M.; Dong, Y.; Vennerstrom, J.L. The synthetic peroxide OZ78 is effective against *Echinostoma caproni* and *Fasciola hepatica*. *J. Antimicrob. Chemother.* **2006**, *58*, 1193–1197. [[CrossRef](#)] [[PubMed](#)]
78. Keiser, J.; Utzinger, J.; Vennerstrom, J.L.; Dong, Y.; Brennan, G.; Fairweather, I. Activity of artemether and OZ78 against triclabendazole-resistant *Fasciola hepatica*. *Trans. R. Soc. Trop. Med. Hyg.* **2007**, *101*, 1219–1222. [[CrossRef](#)] [[PubMed](#)]
79. Keiser, J.; Kirchhofer, C.; Haschke, M.; Huwyler, J.; Dong, Y.; Vennerstrom, J.L.; Vanhoff, K.; Kaminsky, R.; Malikides, N. Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with *Fasciola hepatica* in sheep. *Vet. Parasitol.* **2010**, *173*, 228–235. [[CrossRef](#)] [[PubMed](#)]
80. Meister, I.; Duthaler, U.; Huwyler, J.; Rinaldi, L.; Bosco, A.; Cringoli, G.; Keiser, J. Efficacy and pharmacokinetics of OZ78 and MT04 against a natural infection with *Fasciola hepatica* in sheep. *Vet. Parasitol.* **2013**, *198*, 102–110. [[CrossRef](#)] [[PubMed](#)]

81. Zhao, Q.; Vargas, M.; Dong, Y.; Zhou, L.; Wang, X.; Sriraghavan, K.; Keiser, J.; Vennerstrom, J.L. Structure-activity relationship of an ozonide carboxylic acid (OZ78) against *fasciola hepatica*. *J. Med. Chem.* **2010**, *53*, 4223–4233. [[CrossRef](#)] [[PubMed](#)]
82. Xiao, S.-H.; Keiser, J.; Chollet, J.; Utzinger, J.; Dong, Y.; Endriss, Y.; Vennerstrom, J.L.; Tanner, M. In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. *Antimicrob. Agents Chemother.* **2007**, *51*, 1440–1445. [[CrossRef](#)] [[PubMed](#)]
83. Xiao, S.-H.; Mei, J.-Y.; Jiao, P.-Y. *Schistosoma japonicum*-infected hamsters (*mesocricetus auratus*) used as a model in experimental chemotherapy with praziquantel, artemether, and OZ compounds. *Parasitol. Res.* **2011**, *108*, 431–437. [[CrossRef](#)] [[PubMed](#)]
84. Xiao, S.-H.; Xue, J.; Mei, J.-Y.; Jiao, P.-Y. Effectiveness of synthetic trioxolane OZ78 against *Schistosoma japonicum* in mice and rabbits. *Parasitol. Res.* **2012**, *110*, 2307–2314. [[CrossRef](#)] [[PubMed](#)]
85. Keiser, J.; Ingram, K.; Vargas, M.; Chollet, J.; Wang, X.; Dong, Y.; Vennerstrom, J.L. In vivo activity of aryl ozonides against *Schistosoma* species. *Antimicrob. Agents Chemother.* **2012**, *56*, 1090–1092. [[CrossRef](#)] [[PubMed](#)]
86. Griesbaum, K.; Övez, B.; Huh, T.S.; Dong, Y. Ozonolyses of o-methyloximes in the presence of acid derivatives: A new access to substituted ozonides. *Liebigs Ann.* **1995**, *1995*, 1571–1574. [[CrossRef](#)]
87. Griesbaum, K.; Liu, X.; Kassiaris, A.; Scherer, M. Ozonolyses of o-alkylated ketoximes in the presence of carbonyl groups: A facile access to ozonides. *Liebigs Ann.* **1997**, *1997*, 1381–1390. [[CrossRef](#)]
88. Tang, Y.; Dong, Y.; Karle, J.M.; DiTusa, C.A.; Vennerstrom, J.L. Synthesis of tetrasubstituted ozonides by the Griesbaum cozonolysis reaction: Diastereoselectivity and functional group transformations by post-ozonolysis reactions. *J. Org. Chem.* **2004**, *69*, 6470–6473. [[CrossRef](#)] [[PubMed](#)]
89. Dong, Y.; Chollet, J.; Matile, H.; Charman, S.A.; Chiu, F.C.K.; Charman, W.N.; Scoreneaux, B.; Urwyler, H.; Santo Tomas, J.; Scheurer, C.; et al. Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: Charting a workable structure-activity relationship using simple prototypes. *J. Med. Chem.* **2005**, *48*, 4953–4961. [[CrossRef](#)] [[PubMed](#)]
90. Manzo, E.; Ciavatta, M.L.; Melck, D.; Schupp, P.; de Voogd, N.; Gavagnin, M. Aromatic cyclic peroxides and related keto-compounds from the *Plakortis* sp. Component of a sponge consortium. *J. Nat. Prod.* **2009**, *72*, 1547–1551. [[CrossRef](#)] [[PubMed](#)]
91. Feng, Y.; Davis, R.A.; Sykes, M.; Avery, V.M.; Camp, D.; Quinn, R.J. Antitrypanosomal cyclic polyketide peroxides from the Australian marine sponge *Plakortis* sp. *J. Nat. Prod.* **2010**, *73*, 716–719. [[CrossRef](#)] [[PubMed](#)]
92. Jamison, M.T.; Dalisay, D.S.; Molinski, T.F. Peroxide natural products from *Plakortis zyggompha* and the sponge association *Plakortis halichondrioides*-*Xestospongia deweerdtae*: Antifungal activity against *Cryptococcus gattii*. *J. Nat. Prod.* **2016**, *79*, 555–563. [[CrossRef](#)] [[PubMed](#)]
93. Kobayashi, M.; Kondo, K.; Kitagawa, I. Antifungal peroxyketal acids from an Okinawan marine sponge of *Plakortis* sp. *Chem. Pharm. Bull.* **1993**, *41*, 1324–1326. [[CrossRef](#)] [[PubMed](#)]
94. Rubio, B.K.; Tenney, K.; Ang, K.-H.; Abdulla, M.; Arkin, M.; McKerrow, J.H.; Crews, P. The marine sponge *Diacarnus bismarckensis* as a source of peroxiterpene inhibitors of *Trypanosoma brucei*, the causative agent of sleeping sickness. *J. Nat. Prod.* **2009**, *72*, 218–222. [[CrossRef](#)] [[PubMed](#)]
95. Kashman, Y.; Rotem, M. Muqubilin, a new C₂₄-isoprenoid from a marine sponge. *Tetrahedron Lett.* **1979**, *20*, 1707–1708. [[CrossRef](#)]
96. El Sayed, K.A.; Hamann, M.T.; Hashish, N.E.; Shier, W.T.; Kelly, M.; Khan, A.A. Antimalarial, antiviral, and antitoxoplasmosis norsesterterpene peroxide acids from the Red Sea sponge *Diacarnus erythraeanus*. *J. Nat. Prod.* **2001**, *64*, 522–524. [[CrossRef](#)] [[PubMed](#)]
97. Peng, J.; Shen, X.; El Sayed, K.A.; Dunbar, D.C.; Perry, T.L.; Wilkins, S.P.; Hamann, M.T.; Bobzin, S.; Huesing, J.; Camp, R.; et al. Marine natural products as prototype agrochemical agents. *J. Agric. Food Chem.* **2003**, *51*, 2246–2252. [[CrossRef](#)] [[PubMed](#)]
98. Cheenpracha, S.; Park, E.-J.; Rostama, B.; Pezzuto, J.M.; Chang, L.C. Inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-activated murine macrophage RAW 264.7 cells by the norsesterterpene peroxide, epimuqubilin A. *Mar. Drugs* **2010**, *8*, 429–437. [[CrossRef](#)] [[PubMed](#)]
99. Tanaka, J.; Higa, T.; Suwanborirux, K.; Kokpol, U.; Bernardinelli, G.; Jefford, C.W. Bioactive norsesterterpene 1,2-dioxanes from a Thai sponge, *Mycale* sp. *J. Org. Chem.* **1993**, *58*, 2999–3002. [[CrossRef](#)]
100. Jung, M.; Ham, J.; Song, J. First total synthesis of natural 6-epiplakortolide E. *Org. Lett.* **2002**, *4*, 2763–2765. [[CrossRef](#)] [[PubMed](#)]

101. Perry, T.L.; Dickerson, A.; Khan, A.A.; Kondru, R.K.; Beratan, D.N.; Wipf, P.; Kelly, M.; Hamann, M.T. New peroxy lactones from the Jamaican sponge plakinastrella onkodes, with inhibitory activity against the aids opportunistic parasitic infection toxoplasma gondii. *Tetrahedron* **2001**, *57*, 1483–1487. [[CrossRef](#)]
102. Xu, C.; Schwartz, C.; Raible, J.; Dussault, P.H. Asymmetric synthesis of 1,2-dioxanes: Approaches to the peroxyplakoric acids. *Tetrahedron* **2009**, *65*, 9680–9685. [[CrossRef](#)] [[PubMed](#)]
103. Gemma, S.; Gabellieri, E.; Sanna Coccone, S.; Martí, F.; Tagliatalata-Scafati, O.; Novellino, E.; Campiani, G.; Butini, S. Synthesis of dihydroplakortin, 6-epi-dihydroplakortin, and their c10-desethyl analogues. *J. Org. Chem.* **2010**, *75*, 2333–2340. [[CrossRef](#)] [[PubMed](#)]
104. Barnych, B.; Vatèle, J.-M. Total synthesis of seco-plakortolide E and (–)-ent-plakortolide I: Absolute configurational revision of natural plakortolide I. *Org. Lett.* **2012**, *14*, 564–567. [[CrossRef](#)] [[PubMed](#)]
105. Holla, H.; Labaied, M.; Pham, N.; Jenkins, I.D.; Stuart, K.; Quinn, R.J. Synthesis of antitrypanosomal 1,2-dioxane derivatives based on a natural product scaffold. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4793–4797. [[CrossRef](#)] [[PubMed](#)]
106. Silva, E.M.P.; Pye, R.J.; Brown, G.D.; Harwood, L.M. Towards the total synthesis of mycaperoxide b: Probing biosynthetic rationale. *Eur. J. Org. Chem.* **2012**, *2012*, 1209–1216. [[CrossRef](#)]
107. Kiuchi, F.; Itano, Y.; Uchiyama, N.; Honda, G.; Tsubouchi, A.; Nakajima-Shimada, J.; Aoki, T. Monoterpene hydroperoxides with trypanocidal activity from chenopodium ambrosioides. *J. Nat. Prod.* **2002**, *65*, 509–512. [[CrossRef](#)] [[PubMed](#)]
108. Monzote, L.; Montalvo, A.M.; Almanonni, S.; Scull, R.; Miranda, M.; Abreu, J. Activity of the essential oil from *Chenopodium ambrosioides* grown in Cuba against *Leishmania amazonensis*. *Chemotherapy* **2006**, *52*, 130–136. [[CrossRef](#)] [[PubMed](#)]
109. Wallach, O. Zur kenntnis der terpene und der ätherischen öle. *Justus Liebigs Ann. Chem.* **1912**, *392*, 49–75. [[CrossRef](#)]
110. Nelson, E.K. The composition of oil of chenopodium from various sources. *J. Am. Chem. Soc.* **1920**, *42*, 1204–1208. [[CrossRef](#)]
111. Smillie, W.G.; Pessôa, S.B. A study of the anthelmintic properties of the constituents of the oil of chenopodium. *J. Pharmacol. Exp. Ther.* **1924**, *24*, 359–370.
112. Bodendorf, K. Über ungesättigte peroxyde. Zugleich ein beitrag zur kenntnis der autoxydationsvorgänge. *Arch. Pharm.* **1933**, *271*, 1–35. [[CrossRef](#)]
113. Beckett, A.H.; Donbrow, M.; Jolliffe, G.O. Ascaridole studies: Part iii. The purification and characterisation of ascaridole. *J. Pharm. Pharmacol.* **1955**, *7*, 55–65. [[CrossRef](#)] [[PubMed](#)]
114. Beckett, A.H.; Jolliffe, G.O. A note on the determination of ascaridole in oil of chenopodium. *J. Pharm. Pharmacol.* **1955**, *7*, 606–607. [[CrossRef](#)] [[PubMed](#)]
115. Schenck, G.O.; Ziegler, K. Die synthese des ascaridols. *Naturwissenschaften* **1944**, *32*, 157.
116. Pape, M. Industrial applications of photochemistry. *Pure Appl. Chem.* **1975**, *41*, 535–558. [[CrossRef](#)]
117. Aubry, J.-M.; Bouttemy, S. Preparative oxidation of organic compounds in microemulsions with singlet oxygen generated chemically by the sodium molybdate/hydrogen peroxide system1. *J. Am. Chem. Soc.* **1997**, *119*, 5286–5294. [[CrossRef](#)]
118. Paré, P.W.; Zajicek, J.; Ferracini, V.L.; Melo, I.S. Antifungal terpenoids from chenopodium ambrosioides. *Biochem. Syst. Ecol.* **1993**, *21*, 649–653. [[CrossRef](#)]
119. MacDonald, D.; VanCrey, K.; Harrison, P.; Rangachari, P.K.; Rosenfeld, J.; Warren, C.; Sorger, G. Ascaridole-less infusions of chenopodium ambrosioides contain a nematocide(s) that is(are) not toxic to mammalian smooth muscle. *J. Ethnopharmacol.* **2004**, *92*, 215–221. [[CrossRef](#)] [[PubMed](#)]
120. Gunasekera, S.P.; Gunasekera, M.; Gunawardana, G.P.; McCarthy, P.; Burren, N. Two new bioactive cyclic peroxides from the marine sponge plakortis angulospiculatus. *J. Nat. Prod.* **1990**, *53*, 669–674. [[CrossRef](#)]
121. Yao, G.; Steliou, K. Synthetic studies toward bioactive cyclic peroxides from the marine sponge plakortis angulospiculatus. *Org. Lett.* **2002**, *4*, 485–488. [[CrossRef](#)] [[PubMed](#)]
122. Yu, D.-Q.; Chen, R.-Y.; Huang, L.-J.; Xie, F.-Z.; Ming, D.-S.; Zhou, K.; Li, H.-Y.; Tong, K.-M. The structure and absolute configuration of shuangkangsu: A novel natural cyclic peroxide from *Lonicera japonica* (Thunb.). *J. Asian Nat. Prod. Res.* **2008**, *10*, 851–856. [[CrossRef](#)] [[PubMed](#)]
123. Dias, D.A.; Urban, S. HPLC and NMR studies of phenoxazone alkaloids from pycnoporus cinnabarinus. *Nat. Prod. Commun.* **2009**, *4*, 489–498. [[PubMed](#)]

124. Wang, F.-W. Bioactive metabolites from *Guignardia* sp., an endophytic fungus residing in *Undaria pinnatifida*. *Chin. J. Nat. Med.* **2012**, *10*, 72–76. [[CrossRef](#)] [[PubMed](#)]
125. Barton, D.H.R.; Leclerc, G.; Magnus, P.D.; Menzies, I.D. An unusual synthesis of ergosterol acetate peroxide. *J. Chem. Soc. Chem. Commun.* **1972**, 447–449. [[CrossRef](#)]
126. Jia, M.; Zhao, R.; Xu, B.; Yan, W.; Chu, F.; Gu, H.; Xie, T.; Xiang, H.; Ren, J.; Chen, D.; et al. Synthesis and biological activity evaluation of novel peroxo-bridged derivatives as potential anti-hepatitis b virus agents. *Med. Chem. Comm.* **2017**, *8*, 148–151. [[CrossRef](#)]
127. Macreadie, P.; Avery, T.; Greatrex, B.; Taylor, D.; Macreadie, I. Novel endoperoxides: Synthesis and activity against candida species. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 920–922. [[CrossRef](#)] [[PubMed](#)]
128. Avery, T.D.; Macreadie, P.I.; Greatrex, B.W.; Robinson, T.V.; Taylor, D.K.; Macreadie, I.G. Design of endoperoxides with anti-candida activity. *Bioorg. Med. Chem.* **2007**, *15*, 36–42. [[CrossRef](#)] [[PubMed](#)]
129. Macreadie, I.G.; Avery, T.D.; Robinson, T.V.; Macreadie, P.; Barraclough, M.; Taylor, D.K.; Tiekink, E.R.T. Design of 1,2-dioxines with anti-candida activity: Aromatic substituted 1,2-dioxines. *Tetrahedron* **2008**, *64*, 1225–1232. [[CrossRef](#)]
130. Vil', V.; Yaremenko, I.; Ilovaisky, A.; Terent'ev, A. Synthetic strategies for peroxide ring construction in artemisinin. *Molecules* **2017**, *22*, 117. [[CrossRef](#)] [[PubMed](#)]
131. Kopetzki, D.; Lévesque, F.; Seeberger, P.H. A continuous-flow process for the synthesis of artemisinin. *Chemistry* **2013**, *19*, 5450–5456. [[CrossRef](#)] [[PubMed](#)]
132. Vonwiller, S.C.; Warner, J.A.; Mann, S.T.; Haynes, R.K. Copper(ii) trifluoromethanesulfonate-induced cleavage oxygenation of allylic hydroperoxides derived from qinghao acid in the synthesis of qinghaosu derivatives: Evidence for the intermediacy of enols. *J. Am. Chem. Soc.* **1995**, *117*, 11098–11105. [[CrossRef](#)]
133. Yang, D.M.; Liew, F.Y. Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis. *Parasitology* **1993**, *106*, 7–11. [[CrossRef](#)] [[PubMed](#)]
134. Sen, R.; Bandyopadhyay, S.; Dutta, A.; Mandal, G.; Ganguly, S.; Saha, P.; Chatterjee, M. Artemisinin triggers induction of cell-cycle arrest and apoptosis in leishmania donovani promastigotes. *J. Med. Microbiol.* **2007**, *56*, 1213–1218. [[CrossRef](#)] [[PubMed](#)]
135. Mishina, Y.V.; Krishna, S.; Haynes, R.K.; Meade, J.C. Artemisinins inhibit trypanosoma cruzi and trypanosoma brucei rhodesiense in vitro growth. *Antimicrob. Agents Chemother.* **2007**, *51*, 1852–1854. [[CrossRef](#)] [[PubMed](#)]
136. Ke, O.Y.; Krug, E.C.; Marr, J.J.; Berens, R.L. Inhibition of growth of toxoplasma gondii by qinghaosu and derivatives. *Antimicrob. Agents Chemother.* **1990**, *34*, 1961–1965. [[CrossRef](#)] [[PubMed](#)]
137. Gautam, P.; Upadhyay, S.K.; Hassan, W.; Madan, T.; Sirdeshmukh, R.; Sundaram, C.S.; Gade, W.N.; Basir, S.F.; Singh, Y.; Sarma, P.U. Transcriptomic and proteomic profile of aspergillus fumigatus on exposure to artemisinin. *Mycopathologia* **2011**, *172*, 331. [[CrossRef](#)] [[PubMed](#)]
138. Buragohain, P.; Surineni, N.; Barua, N.C.; Bhuyan, P.D.; Boruah, P.; Borah, J.C.; Laisharm, S.; Moirangthem, D.S. Synthesis of a novel series of fluoroarene derivatives of artemisinin as potent antifungal and anticancer agent. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 3338–3341. [[CrossRef](#)] [[PubMed](#)]
139. Oguariri, R.M.; Adelsberger, J.W.; Baseler, M.W.; Imamichi, T. Evaluation of the effect of pyrimethamine, an anti-malarial drug, on hiv-1 replication. *Virus Res.* **2010**, *153*, 269–276. [[CrossRef](#)] [[PubMed](#)]
140. Paeshuyse, J.; Coelmont, L.; Vliegen, I.; Hemel, J.V.; Vandekerckhove, J.; Peys, E.; Sas, B.; Clercq, E.D.; Neyts, J. Hemin potentiates the anti-hepatitis c virus activity of the antimalarial drug artemisinin. *Biochem. Biophys. Res. Commun.* **2006**, *348*, 139–144. [[CrossRef](#)] [[PubMed](#)]
141. Romero, M.R.; Serrano, M.A.; Vallejo, M.; Efferth, T.; Alvarez, M.; Marin, J.J.G. Antiviral effect of artemisinin from artemisia annua against a model member of the flaviviridae family, the bovine viral diarrhoea virus (BVDV). *Planta Med.* **2006**, *72*, 1169–1174. [[CrossRef](#)] [[PubMed](#)]
142. Parvez, M.K.; Arbab, A.H.; Al-Dosari, M.S.; Al-Rehaily, A.J. Antiviral natural products against chronic hepatitis b: Recent developments. *Curr. Pharm. Des.* **2016**, *22*, 286–293. [[CrossRef](#)] [[PubMed](#)]
143. Li, Y.-S.; Chen, H.-G.; He, H.-B.; Hou, X.-Y.; Ellis, M.; McManus, D.P. A double-blind field trial on the effects of artemether on schistosoma japonicum infection in a highly endemic focus in southern china. *Acta Trop.* **2005**, *96*, 184–190. [[CrossRef](#)] [[PubMed](#)]
144. O'Neill, J.F.; Johnston, R.C.; Halferty, L.; Hanna, R.E.B.; Brennan, G.P.; Fairweather, I. A comparative study on the impact of two artemisinin derivatives, artemether and artesunate, on the female reproductive system of fasciola hepatica. *Vet. Parasitol.* **2015**, *211*, 182–194. [[CrossRef](#)] [[PubMed](#)]

145. O'Neill, J.F.; Johnston, R.C.; Halferty, L.; Hanna, R.E.B.; Brennan, G.P.; Fairweather, I. Disruption of spermatogenesis in the liver fluke, *fasciola hepatica* by two artemisinin derivatives, artemether and artesunate. *J. Helminthol.* **2017**, *91*, 55–71. [[CrossRef](#)] [[PubMed](#)]
146. Keiser, J.; Sayed, H.; El-Ghanam, M.; Sabry, H.; Anani, S.; El-Wakeel, A.; Hatz, C.; Utzinger, J.; El-Din, S.S.; El-Maadawy, W.; et al. Efficacy and safety of artemether in the treatment of chronic fascioliasis in egypt: Exploratory phase-2 trials. *PLoS Negl. Trop. Dis.* **2011**, *5*, e1285. [[CrossRef](#)] [[PubMed](#)]
147. Jones-Brando, L.; D'Angelo, J.; Posner, G.H.; Yolken, R. In vitro inhibition of toxoplasma gondii by four new derivatives of artemisinin. *Antimicrob. Agents Chemother.* **2006**, *50*, 4206–4208. [[CrossRef](#)] [[PubMed](#)]
148. Cuzzocrea, S.; Saadat, F.; Di Paola, R.; Mirshafiey, A. Artemether: A new therapeutic strategy in experimental rheumatoid arthritis. *Immunopharmacol. Immunotoxicol.* **2005**, *27*, 615–630. [[CrossRef](#)] [[PubMed](#)]
149. Wang, J.X.; Tang, W.; Shi, L.P.; Wan, J.; Zhou, R.; Ni, J.; Fu, Y.F.; Yang, Y.F.; Li, Y.; Zuo, J.P. Investigation of the immunosuppressive activity of artemether on t-cell activation and proliferation. *Br. J. Pharmacol.* **2007**, *150*, 652–661. [[CrossRef](#)] [[PubMed](#)]
150. Haynes, R.K.; Vonwiller, S.C. Extraction of artemisinin and artemisinic acid: Preparation of artemether and new analogues. *Trans. R. Soc. Trop. Med. Hyg.* **1994**, *88*, 23–26. [[CrossRef](#)]
151. Stringham, R.W.; Teager, D.S. Streamlined process for the conversion of artemisinin to artemether. *Org. Process Res. Dev.* **2012**, *16*, 764–768. [[CrossRef](#)]
152. Gilmore, K.; Kopetzki, D.; Lee, J.W.; Horvath, Z.; McQuade, D.T.; Seidel-Morgenstern, A.; Seeberger, P.H. Continuous synthesis of artemisinin-derived medicines. *Chem. Commun.* **2014**, *50*, 12652–12655. [[CrossRef](#)] [[PubMed](#)]
153. Yaseneva, P.; Plaza, D.; Fan, X.; LoPONOV, K.; Lapkin, A. Synthesis of the antimalarial API artemether in a flow reactor. *Catal. Today* **2015**, *239*, 90–96. [[CrossRef](#)]
154. Li, S.; Wu, L.; Liu, Z.; Hu, L.; Xu, P.; Xuan, Y.; Liu, Y.; Liu, X.; Fan, J. Studies on prophylactic effect of artesunate on schistosomiasis japonica. *Chin. Med. J.* **1996**, *109*, 848–853. [[PubMed](#)]
155. Liu, R.; Dong, H.-F.; Guo, Y.; Zhao, Q.-P.; Jiang, M.-S. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: A systematic review and meta-analysis. *Parasites Vectors* **2011**, *4*, 201. [[CrossRef](#)] [[PubMed](#)]
156. Hien, T.T.; Truong, N.T.; Minh, N.H.; Dat, H.D.; Dung, N.T.; Hue, N.T.; Dung, T.K.; Tuan, P.Q.; Campbell, J.I.; Farrar, J.J.; et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. *Am. J. Trop. Med. Hyg.* **2008**, *78*, 388–392. [[PubMed](#)]
157. Romero, M.R.; Efferth, T.; Serrano, M.A.; Castaño, B.; Macias, R.I.R.; Briz, O.; Marin, J.J.G. Effect of artemisinin/artesunate as inhibitors of hepatitis b virus production in an “in vitro” replicative system. *Antivir. Res.* **2005**, *68*, 75–83. [[CrossRef](#)] [[PubMed](#)]
158. Dai, R.; Xiao, X.; Peng, F.; Li, M.; Gong, G. Artesunate, an anti-malarial drug, has a potential to inhibit hcv replication. *Virus Genes* **2016**, *52*, 22–28. [[CrossRef](#)] [[PubMed](#)]
159. Milbradt, J.; Auerochs, S.; Korn, K.; Marschall, M. Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum anti-infective drug artesunate. *J. Clin. Virol.* **2009**, *46*, 24–28. [[CrossRef](#)] [[PubMed](#)]
160. Hakacova, N.; Klingel, K.; Kandolf, R.; Engdahl, E.; Fogdell-Hahn, A.; Higgins, T. First therapeutic use of artesunate in treatment of human herpesvirus 6b myocarditis in a child. *J. Clin. Virol.* **2013**, *57*, 157–160. [[CrossRef](#)] [[PubMed](#)]
161. Efferth, T.; Marschall, M.; Wang, X.; Huong, S.-M.; Hauber, I.; Olbrich, A.; Kronschnabl, M.; Stamminger, T.; Huang, E.-S. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. *J. Mol. Med.* **2002**, *80*, 233–242. [[CrossRef](#)] [[PubMed](#)]
162. Flobinus, A.; Taudon, N.; Desbordes, M.; Labrosse, B.; Simon, F.; Mazon, M.-C.; Schnepf, N. Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. *J. Antimicrob. Chemother.* **2014**, *69*, 34–40. [[CrossRef](#)] [[PubMed](#)]
163. Zeng, A.-H.; Ou, Y.-Y.; Guo, M.-M.; Dai, X.; Zhou, D.-Z.; Chen, R. Human embryonic lung fibroblasts treated with artesunate exhibit reduced rates of proliferation and human cytomegalovirus infection in vitro. *J. Thorac. Dis.* **2015**, *7*, 1151–1157. [[PubMed](#)]
164. Chou, S.; Marousek, G.; Auerochs, S.; Stamminger, T.; Milbradt, J.; Marschall, M. The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. *Antivir. Res.* **2011**, *92*, 364–368. [[CrossRef](#)] [[PubMed](#)]

165. Menon, R.B.; Kanno, M.M.; Tekwani, B.L.; Gut, J.; Rosenthal, P.J.; Avery, M.A. A new library of c-16 modified artemisinin analogs and evaluation of their anti-parasitic activities. *Combinatorial Chem. High Throughput Screen.* **2006**, *9*, 729–741. [[CrossRef](#)]
166. D'Angelo, J.G.; Bordón, C.; Posner, G.H.; Yolken, R.; Jones-Brando, L. Artemisinin derivatives inhibit toxoplasma gondii in vitro at multiple steps in the lytic cycle. *J. Antimicrob. Chemother.* **2009**, *63*, 146–150. [[CrossRef](#)] [[PubMed](#)]
167. Galal, A.M.; Ross, S.A.; Jacob, M.; ElSohly, M.A. Antifungal activity of artemisinin derivatives. *J. Nat. Prod.* **2005**, *68*, 1274–1276. [[CrossRef](#)] [[PubMed](#)]
168. Lin, A.J.; Lee, M.; Klayman, D.L. Antimalarial activity of new water-soluble dihydroartemisinin derivatives. 2. Stereospecificity of the ether side chain. *J. Med. Chem.* **1989**, *32*, 1249–1252. [[CrossRef](#)] [[PubMed](#)]
169. Bossi, A.; Venugopalan, B.; Dominguez Gerpe, L.; Yeh, H.J.C.; Flippen-Anderson, J.L.; Buchs, P.; Luo, X.D.; Milhous, W.; Peters, W. Arteether, a new antimalarial drug: Synthesis and antimalarial properties. *J. Med. Chem.* **1988**, *31*, 645–650. [[CrossRef](#)] [[PubMed](#)]
170. Jung, M.; Schinazi, R.F. Synthesis and in vitro anti-human immunodeficiency virus activity of artemisinin (qinghaosu)-related trioxanes. *Bioorg. Med. Chem. Lett.* **1994**, *4*, 931–934. [[CrossRef](#)]
171. Blazquez, A.G.; Fernandez-Dolon, M.; Sanchez-Vicente, L.; Maestre, A.D.; Gomez-San Miguel, A.B.; Alvarez, M.; Serrano, M.A.; Jansen, H.; Efferth, T.; Marin, J.J.G.; et al. Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. *Bioorg. Med. Chem.* **2013**, *21*, 4432–4441. [[CrossRef](#)] [[PubMed](#)]
172. Jung, M.; Bustos, D.A.; ElSohly, H.N.; McChesney, J.D. A concise and stereoselective synthesis of (+)-12-n-butyldeoxyartemisinin. *Synlett* **1990**, *1990*, 743–744. [[CrossRef](#)]
173. Aminake, M.N.; Mahajan, A.; Kumar, V.; Hans, R.; Wiesner, L.; Taylor, D.; de Kock, C.; Grobler, A.; Smith, P.J.; Kirschner, M.; et al. Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy. *Bioorg. Med. Chem.* **2012**, *20*, 5277–5289. [[CrossRef](#)] [[PubMed](#)]
174. Slade, D.; Galal, A.M.; Gul, W.; Radwan, M.M.; Ahmed, S.A.; Khan, S.I.; Tekwani, B.L.; Jacob, M.R.; Ross, S.A.; ElSohly, M.A. Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers. *Bioorg. Med. Chem.* **2009**, *17*, 7949–7957. [[CrossRef](#)] [[PubMed](#)]
175. Posner, G.H.; Paik, I.-H.; Sur, S.; McRiner, A.J.; Borstnik, K.; Xie, S.; Shapiro, T.A. Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. *J. Med. Chem.* **2003**, *46*, 1060–1065. [[CrossRef](#)] [[PubMed](#)]
176. Arav-Boger, R.; He, R.; Chiou, C.-J.; Liu, J.; Woodard, L.; Rosenthal, A.; Jones-Brando, L.; Forman, M.; Posner, G. Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers. *PLoS ONE* **2010**, *5*, e10370. [[CrossRef](#)] [[PubMed](#)]
177. Roy, S.; He, R.; Kapoor, A.; Forman, M.; Mazzone, J.R.; Posner, G.H.; Arav-Boger, R. Inhibition of human cytomegalovirus replication by artemisinins: Effects mediated through cell cycle modulation. *Antimicrob. Agents Chemother.* **2015**, *59*, 3870–3879. [[CrossRef](#)] [[PubMed](#)]
178. Rosenthal, A.S.; Chen, X.; Liu, J.O.; West, D.C.; Hergenrother, P.J.; Shapiro, T.A.; Posner, G.H. Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells. *J. Med. Chem.* **2009**, *52*, 1198–1203. [[CrossRef](#)] [[PubMed](#)]
179. Alagbala, A.A.; McRiner, A.J.; Borstnik, K.; Labonte, T.; Chang, W.; D'Angelo, J.G.; Posner, G.H.; Foster, B.A. Biological mechanisms of action of novel c-10 non-acetal trioxane dimers in prostate cancer cell lines. *J. Med. Chem.* **2006**, *49*, 7836–7842. [[CrossRef](#)] [[PubMed](#)]
180. He, R.; Mott, B.T.; Rosenthal, A.S.; Genna, D.T.; Posner, G.H.; Arav-Boger, R. An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities. *PLoS ONE* **2011**, *6*, e24334. [[CrossRef](#)] [[PubMed](#)]
181. He, R.; Park, K.; Cai, H.; Kapoor, A.; Forman, M.; Mott, B.; Posner, G.H.; Arav-Boger, R. Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication. *Antimicrob. Agents Chemother.* **2012**, *56*, 3508–3515. [[CrossRef](#)] [[PubMed](#)]
182. He, R.; Forman, M.; Mott, B.T.; Venkatadri, R.; Posner, G.H.; Arav-Boger, R. Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety. *Antimicrob. Agents Chemother.* **2013**, *57*, 4208–4214. [[CrossRef](#)] [[PubMed](#)]

183. Mott, B.T.; He, R.; Chen, X.; Fox, J.M.; Civin, C.I.; Arav-Boger, R.; Posner, G.H. Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-cmv) and anti-cancer agents: A structure-activity study. *Bioorg. Med. Chem.* **2013**, *21*, 3702–3707. [[CrossRef](#)] [[PubMed](#)]
184. Reiter, C.; Fröhlich, T.; Gruber, L.; Hutterer, C.; Marschall, M.; Voigtländer, C.; Friedrich, O.; Kappes, B.; Efferth, T.; Tsogoeva, S.B. Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities. *Bioorg. Med. Chem.* **2015**, *23*, 5452–5458. [[CrossRef](#)] [[PubMed](#)]
185. Hutterer, C.; Niemann, I.; Milbradt, J.; Fröhlich, T.; Reiter, C.; Kadioglu, O.; Bahsi, H.; Zeitträger, I.; Wagner, S.; Einsiedel, J.; et al. The broad-spectrum anti-infective drug artesunate interferes with the canonical nuclear factor kappa b (Nf- κ B) pathway by targeting RelA/p65. *Antivir. Res.* **2015**, *124*, 101–109. [[CrossRef](#)] [[PubMed](#)]
186. Reiter, C.; Fröhlich, T.; Zeino, M.; Marschall, M.; Bahsi, H.; Leidenberger, M.; Friedrich, O.; Kappes, B.; Hampel, F.; Efferth, T.; et al. New efficient artemisinin derived agents against human leukemia cells, human cytomegalovirus and plasmodium falciparum: 2nd generation 1,2,4-trioxane-ferrocene hybrids. *Eur. J. Med. Chem.* **2015**, *97*, 164–172. [[CrossRef](#)] [[PubMed](#)]
187. Obeid, S.; Alen, J.; Nguyen, V.H.; Pham, V.C.; Meuleman, P.; Pannecouque, C.; Le, T.N.; Neyts, J.; Dehaen, W.; Paeshuyse, J. Artemisinin analogues as potent inhibitors of in vitro hepatitis c virus replication. *PLoS ONE* **2013**, *8*, e81783. [[CrossRef](#)] [[PubMed](#)]
188. Wang, X.; Zhao, Q.; Vargas, M.; Dong, Y.; Sriraghavan, K.; Keiser, J.; Vennerstrom, J.L. The activity of dispiro peroxides against fasciola hepatica. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5320–5323. [[CrossRef](#)] [[PubMed](#)]
189. Amewu, R.; Stachulski, A.V.; Ward, S.A.; Berry, N.G.; Bray, P.G.; Davies, J.; Labat, G.; Vivas, L.; O'Neill, P.M. Design and synthesis of orally active dispiro 1,2,4,5-tetraoxanes; synthetic antimalarials with superior activity to artemisinin. *Organ. Biomol. Chem.* **2006**, *4*, 4431–4436. [[CrossRef](#)] [[PubMed](#)]
190. Duan, W.-W.; Qiu, S.-J.; Zhao, Y.; Sun, H.; Qiao, C.; Xia, C.-M. Praziquantel derivatives exhibit activity against both juvenile and adult schistosoma japonicum. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 1587–1590. [[CrossRef](#)] [[PubMed](#)]
191. Yang, J.-J.; Boissier, J.; Chen, J.-L.; Yao, H.; Yang, S.; Rognon, A.; Qiao, C. Design, synthesis and biological evaluation of praziquantel and endoperoxide conjugates as antischistosomal agents. *Future Med. Chem.* **2015**, *7*, 713–725. [[CrossRef](#)] [[PubMed](#)]
192. Cowan, N.; Yaremenko, I.A.; Krylov, I.B.; Terent'ev, A.O.; Keiser, J. Elucidation of the in vitro and in vivo activities of bridged 1,2,4-trioxolanes, bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides, silyl peroxides, and hydroxylamine derivatives against schistosoma mansoni. *Bioorg. Med. Chem.* **2015**, *23*, 5175–5181. [[CrossRef](#)] [[PubMed](#)]
193. Terent'ev, A.O.; Borisov, D.A.; Chernyshev, V.V.; Nikishin, G.I. Facile and selective procedure for the synthesis of bridged 1,2,4,5-tetraoxanes; strong acids as cosolvents and catalysts for addition of hydrogen peroxide to β -diketones. *J. Org. Chem.* **2009**, *74*, 3335–3340. [[CrossRef](#)] [[PubMed](#)]
194. Terent'ev, A.O.; Yaremenko, I.A.; Vil, V.A.; Moiseev, I.K.; Kon'kov, S.A.; Dembitsky, V.M.; Levitsky, D.O.; Nikishin, G.I. Phosphomolybdic and phosphotungstic acids as efficient catalysts for the synthesis of bridged 1,2,4,5-tetraoxanes from [small beta]-diketones and hydrogen peroxide. *Org. Biomol. Chem.* **2013**, *11*, 2613–2623. [[CrossRef](#)] [[PubMed](#)]
195. Shul'pin, G.B. Metal-catalyzed hydrocarbon oxygenations in solutions: The dramatic role of additives: A review. *J. Mol. Catal. A Chem.* **2002**, *189*, 39–66. [[CrossRef](#)]
196. Wu, X.-F.; Gong, J.-L.; Qi, X. A powerful combination: Recent achievements on using tba1 and tbbp as oxidation system. *Org. Biomol. Chem.* **2014**, *12*, 5807–5817. [[CrossRef](#)] [[PubMed](#)]
197. Saiz, A.I.; Manrique, G.D.; Fritz, R. Determination of benzoyl peroxide and benzoic acid levels by hplc during wheat flour bleaching process. *J. Agric. Food Chem.* **2001**, *49*, 98–102. [[CrossRef](#)] [[PubMed](#)]
198. Abe-Onishi, Y.; Yomota, C.; Sugimoto, N.; Kubota, H.; Tanamoto, K. Determination of benzoyl peroxide and benzoic acid in wheat flour by high-performance liquid chromatography and its identification by high-performance liquid chromatography-mass spectrometry. *J. Chromatogr. A* **2004**, *1040*, 209–214. [[CrossRef](#)] [[PubMed](#)]
199. Mu, G.; Liu, H.; Gao, Y.; Luan, F. Determination of benzoyl peroxide, as benzoic acid, in wheat flour by capillary electrophoresis compared with hplc. *J. Sci. Food Agric.* **2012**, *92*, 960–964. [[CrossRef](#)] [[PubMed](#)]
200. Cotterill, J.A. Benzoyl peroxide. *Acta Derm.-Venereol. Suppl.* **1980**, (Suppl. S89), 57–63.

201. Leyden, J.J.; Wortzman, M.; Baldwin, E.K. Antibiotic-resistant propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. *Cutis* **2008**, *82*, 417–421. [[PubMed](#)]
202. Burkhart, C.G.; Burkhart, C.N.; Isham, N. Synergistic antimicrobial activity by combining an allylamine with benzoyl peroxide with expanded coverage against yeast and bacterial species. *Br. J. Dermatol.* **2006**, *154*, 341–344. [[CrossRef](#)] [[PubMed](#)]
203. Hegemann, L.; Toso, S.M.; Kitay, K.; Webster, C.F. Anti-inflammatory actions of benzoyl peroxide: Effects on the generation of reactive oxygen species by leucocytes and the activity of protein kinase c and calmodulin. *Br. J. Dermatol.* **1994**, *130*, 569–575. [[CrossRef](#)] [[PubMed](#)]
204. Waller, J.M.; Dreher, F.; Behnam, S.; Ford, C.; Lee, C.; Tiet, T.; Weinstein, G.D.; Maibach, H.I. ‘Keratolytic’ properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man. *Skin Pharmacol. Physiol.* **2006**, *19*, 283–289. [[CrossRef](#)] [[PubMed](#)]
205. Merker, P.C. Benzoyl peroxide: A history of early research and researchers. *Int. J. Dermatol.* **2002**, *41*, 185–188. [[CrossRef](#)] [[PubMed](#)]
206. Alvarez, O.M.; Mertz, P.M.; Eaglstein, W.H. Benzoyl peroxide and epidermal wound healing. *Arch. Dermatol.* **1983**, *119*, 222–225. [[CrossRef](#)] [[PubMed](#)]
207. Sagransky, M.; Yentzer, B.A.; Feldman, S.R. Benzoyl peroxide: A review of its current use in the treatment of acne vulgaris. *Expert Opin. Pharmacother.* **2009**, *10*, 2555–2562. [[CrossRef](#)] [[PubMed](#)]
208. Burkhart, C.G.; Burkhart, C.N. The chemistry and synergy of benzoyl peroxide with clindamycin. *Br. J. Dermatol.* **2008**, *159*, 480–481. [[CrossRef](#)] [[PubMed](#)]
209. Kaur, J.; Sehgal, V.K.; Gupta, A.K.; Singh, S.P. A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris. *Int. J. Appl. Basic Med. Res.* **2015**, *5*, 106–110. [[CrossRef](#)] [[PubMed](#)]
210. Burkhart, C.G.; Burkhart, C.N. Treatment of acne vulgaris without antibiotics: Tertiary amine-benzoyl peroxide combination vs. Benzoyl peroxide alone (proactiv solution™). *Int. J. Dermatol.* **2007**, *46*, 89–93. [[CrossRef](#)] [[PubMed](#)]
211. Price, C.C.; Krebs, E. P-nitrobenzoyl peroxide. *Org. Synth.* **1943**, *23*, 65.
212. Her, B.; Jones, A.; Wollack, J.W. A three-step synthesis of benzoyl peroxide. *J. Chem. Educ.* **2014**, *91*, 1491–1494. [[CrossRef](#)]
213. La Barge, R.G.; Johnson, G.L. Preparation of Benzoyl Peroxide. U.S. Patent 3,674,858, 4 July 1972.
214. Wright, J.J.K.; Merrill, Y.; Puar, M.S.; McPhail, A.T. Structure of oxanthromicin (antibiotic 16-550), a novel dimeric anthrone peroxide. *J. Chem. Soc. Chem. Commun.* **1984**, 473–474. [[CrossRef](#)]
215. Patel, M.; Horan, A.C.; Gullo, V.P.; Loebenberg, D.; Marquez, J.A.; Miller, G.H.; Waltz, J.A. Oxanthromicin, a novel antibiotic from actinomadura. *J. Antibiot.* **1984**, *37*, 413–415. [[CrossRef](#)] [[PubMed](#)]
216. Otaguro, K.; Iwatsuki, M.; Ishiyama, A.; Namatame, M.; Nishihara-Tukashima, A.; Kiyohara, H.; Hashimoto, T.; Asakawa, Y.; Omura, S.; Yamada, H. In vitro antitrypanosomal activity of plant terpenes against trypanosoma brucei. *Phytochemistry* **2011**, *72*, 2024–2030. [[CrossRef](#)] [[PubMed](#)]
217. Tropina, V.I.; Krivykh, O.V.; Sadchikova, N.P.; Terent’ev, A.O.; Krylov, I.B. Synthesis and antimicrobial activity of geminal bis-hydroperoxides. *Pharm. Chem. J.* **2010**, *44*, 248–250. [[CrossRef](#)]

